Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590
Wakelee, H. A., Stephenson, P., Keller, S. M., Wagner, H., Herskovic, A., Komaki, R., … Johnson, D. H. (2005). Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. LUNG CANCER. CHICAGO,IL,IL,IL: ELSEVIER IRELAND LTD.

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., Ford, J. M., … Sikic, B. I. (2005). Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(24), 5613–19.

Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: Novel agents with potential in lung cancer
Wakelee, H. A., & Schiller, J. H. (2005). Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: Novel agents with potential in lung cancer. CLINICAL LUNG CANCER, 7, S31–S38.

Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors
Wakelee, H. A., & Sikic, B. I. (2005). Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors. CLINICAL LUNG CANCER, 7, S6–S12.

Second- and third-line treatments in non-small cell lung cancer.
Kumar, A., & Wakelee, H. (2006). Second- and third-line treatments in non-small cell lung cancer. Current Treatment Options in Oncology, 7(1), 37–49.

Optimizing first-line treatment options for patients with advanced NSCLC
Wakelee, H., & Belani, C. P. (2005). Optimizing first-line treatment options for patients with advanced NSCLC. ONCOLOGIST, 10, 1–10.

An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers
Le, Q. T., Chen, E., Salim, A., Cao, H. B., Kong, C. S., Whyte, R., … Giaccia, A. J. (2006). An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. CLINICAL CANCER RESEARCH, 12(5), 1507–14.

Changes in the natural history of nonsmall cell lung cancer (NSCLC) - Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990
Wakelee, H. A., Bernardo, P., Johnson, D. H., & Schiller, J. H. (2006). Changes in the natural history of nonsmall cell lung cancer (NSCLC) - Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. CANCER. ORLANDO,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL: JOHN WILEY & SONS INC.

Sunitinib: A newly approved small-molecule inhibitor of angiogenesis
Cabebe, E., & Wakelee, H. (2006). Sunitinib: A newly approved small-molecule inhibitor of angiogenesis. DRUGS OF TODAY, 42(6), 387–98.

Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: Implications for the new intergroup trial
Wakelee, H. A., Schiller, J. H., & Gandara, D. R. (2006). Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: Implications for the new intergroup trial. CLINICAL LUNG CANCER, 8(1), 18–21.

Lung cancer in women: Exploring sex differences in susceptibility, biology, and therapeutic response
Donington, J. S., Le, Q.-T., & Wakelee, H. A. (2006). Lung cancer in women: Exploring sex differences in susceptibility, biology, and therapeutic response. CLINICAL LUNG CANCER, 8(1), 22–29.

A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma
Roy, M. S., Le, Q.-T., Donington, J. S., & Wakelee, H. A. (2006). A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma. CLINICAL LUNG CANCER, 8(2), 146–48.

Lung cancer incidence in never smokers
Wakelee, H. A., Chang, E. T., Gomez, S. L., Keegan, T. H., Feskanich, D., Clarke, C. A., … West, D. W. (2007). Lung cancer incidence in never smokers. JOURNAL OF CLINICAL ONCOLOGY, 25(5), 472–78.

Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease
Wakelee, H., Dubey, S., & Gandara, D. (2007). Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease. ONCOLOGIST, 12(3), 331–37.

Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594
Wakelee, H. A., Wang, W., Schiller, J. H., Langer, C. J., Sandler, A. B., Belani, C. P., & Johnson, D. H. (2006). Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. JOURNAL OF THORACIC ONCOLOGY. BARCELONA,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN: LIPPINCOTT WILLIAMS & WILKINS.

Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors
Le, Q.-T., Loo, B. W., Ho, A., Cotrutz, C., Koong, A. C., Wakelee, H., … Donington, J. (2006). Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. JOURNAL OF THORACIC ONCOLOGY, 1(8), 802–9.

Adjuvant chemotherapy of stage I non-small cell lung cancer in North America
Gandara, D. R., Wakelee, H., Calhoun, R., & Jablons, D. (2007). Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. JOURNAL OF THORACIC ONCOLOGY, 2(7), S125–S127.

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe, E., & Wakelee, H. (2007). Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Current Treatment Options in Oncology, 8(1), 15–27.

Metabolic tumor burden predicts for disease progression and death in lung cancer
Lee, P., Weerasuriya, D. K., Lavori, P. W., Quon, A., Hara, W., Maxim, P. G., … Loo, B. W. (2007). Metabolic tumor burden predicts for disease progression and death in lung cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(2), 328–33.

Cooperative group research efforts in lung cancer: Focus on early-stage non-small-cell lung cancer
Wakelee, H., Langer, C., Vokes, E., Schiller, J., Baas, P., Saijo, N., … Gandara, D. R. (2008). Cooperative group research efforts in lung cancer: Focus on early-stage non-small-cell lung cancer. CLINICAL LUNG CANCER, 9(1), 9–15.

Lung cancer presenting with amegakaryocytic thrombocytopenia.
Witteles, W. H., Schrier, S. L., & Wakelee, H. A. (2008). Lung cancer presenting with amegakaryocytic thrombocytopenia. Journal of Clinical Oncology , 26(7), 1171–74.

Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress?
Langer, C. J., Wakelee, H., Schiller, J., Choy, H., Shepherd, F., Vokes, E. E., … Gandara, D. R. (2008). Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress? CLINICAL LUNG CANCER, 9(2), 85–91.

Complications of ablative therapies in lung cancer
Padda, S., Kothary, N., Donington, J., Cannon, W., Loo, B. W., Kee, S., & Wakelee, H. (2008). Complications of ablative therapies in lung cancer. CLINICAL LUNG CANCER, 9(2), 122–26.

Summary statement - Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy
Lynch, T. J., Blumenschein, G. R., Engelman, J. A., Espinoza-Delgado, I., Govindan, R., Hanke, J., … Weitzman, A. (2008). Summary statement - Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. JOURNAL OF THORACIC ONCOLOGY, 3(6), S107–S112.

Antibodies to vascular endothelial growth factor in non-small cell lung cancer
Wakelee, H. (2008). Antibodies to vascular endothelial growth factor in non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 3(6), S113–S118.

Sex differences in lung-cancer susceptibility: a smoke screen?
Wakelee, H. A., Gomez, S. L., & Chang, E. T. (2008). Sex differences in lung-cancer susceptibility: a smoke screen? LANCET ONCOLOGY, 9(7), 609–10.

Adjuvant chemotherapy for resected non-small cell lung cancer.
Wakelee, H., & Chhatwani, L. (2008). Adjuvant chemotherapy for resected non-small cell lung cancer. Seminars in Thoracic and Cardiovascular Surgery, 20(3), 198–203.

Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non-Small-Cell Lung Cancer
Wakelee, H., Kernstine, K., Vokes, E., Schiller, J., Baas, P., Saijo, N., … Putnam, J. "B. (2008). Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 9(6), 346–51.

PEMETREXED DISODIUM FOR THE TREATMENT OF NSCLC: AN UPDATE
Hsu, J. Y., & Wakelee, H. (2008). PEMETREXED DISODIUM FOR THE TREATMENT OF NSCLC: AN UPDATE. DRUGS OF TODAY, 44(9), 669–78.

Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial
West, H. L., Wakelee, H. A., Perry, M. C., Belt, R. J., Chen, R., & Obasaju, C. (2009). Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. ANNALS OF ONCOLOGY, 20(5), 850–56.

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy
Krupitskaya, Y., Eslamy, H. K., Nguyen, D. D., Kumar, A., & Wakelee, H. A. (2009). Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy. JOURNAL OF THORACIC ONCOLOGY, 4(3), 429–31.

Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer
Krupitskaya, Y., & Wakelee, H. A. (2009). Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 10(6), 597–605.

Uncovering Disparities in Survival after Non-Small-Cell Lung Cancer among Asian/Pacific Islander Ethnic Populations in California
Chang, E. T., Shema, S. J., Wakelee, H. A., Clarke, C. A., & Gomez, S. L. (2009). Uncovering Disparities in Survival after Non-Small-Cell Lung Cancer among Asian/Pacific Islander Ethnic Populations in California. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 18(8), 2248–55.

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., Miceli, R., … Tolcher, A. W. (2010). Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. ANNALS OF ONCOLOGY, 21(2), 376–81.

Review of erlotinib in the treatment of advanced non-small cell lung cancer.
Ganjoo, K. N., & Wakelee, H. (2007). Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics : Targets & Therapy, 1(4), 335–46.

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy
Hsu, J. Y., & Wakelee, H. A. (2009). Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy. BIODRUGS, 23(5), 289–304.

Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial
Chlebowski, R. T., Schwartz, A. G., Wakelee, H., Anderson, G. L., Stefanick, M. L., Manson, J. A. E., … Hubbell, F. A. (2009). Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. LANCET, 374(9697), 1243–51.

Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress
Wakelee, H., Loo, B. W., Kernstine, K. H., Putnam, J. B., Edelman, M. J., Vokes, E. E., … Gandara, D. R. (2009). Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. CLINICAL LUNG CANCER, 10(6), 395–404.

Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer A Review
Clement-Duchene, C., & Wakelee, H. (2010). Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer A Review. JOURNAL OF THORACIC ONCOLOGY, 5(1), 129–39.

Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir
Chapman, C. H., Shen, J., Filion, E. J., Tran, P. T., Hara, W., Asuncion, A., … Green, J. (2009). Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir. JOURNAL OF THORACIC ONCOLOGY, 4(12), 1587–89.

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules
Advani, R. H., Hurwitz, H. I., Gordon, M. S., Ebbinghaus, S. W., Mendelson, D. S., Wakelee, H. A., … Adelman, D. C. (2010). Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. CLINICAL CANCER RESEARCH, 16(7), 2167–75.

AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer
Neal, J., & Wakelee, H. (2010). AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 12(4), 487–95.

Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial
Chlebowski, R. T., Anderson, G. L., Manson, J. A. E., Schwartz, A. G., Wakelee, H., Gass, M., … Stefanick, M. L. (2010). Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 102(18), 1413–21.

A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., Kumar, A., … Wakelee, H. A. (2010). A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 5(11), 1821–25.

Vascular Disrupting Agents
Das, M., & Wakelee, H. (2010). Vascular Disrupting Agents. JOURNAL OF THORACIC ONCOLOGY, 5(12), S482–S483.

Survival following Non-Small Cell Lung Cancer among Asian/Pacific Islander, Latina, and Non-Hispanic White Women Who Have Never Smoked
Gomez, S. L., Chang, E. T., Shema, S. J., Fish, K., Sison, J. D., Reynolds, P., … Wakelee, H. A. (2011). Survival following Non-Small Cell Lung Cancer among Asian/Pacific Islander, Latina, and Non-Hispanic White Women Who Have Never Smoked. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 20(3), 545–54.

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Keedy, V. L., Temin, S., Somerfield, M. R., Beasley, M. B., Johnson, D. H., McShane, L. M., … Giaccone, G. (2011). American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 2121–27.

Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer
Lee, P., Bazan, J. G., Lavori, P. W., Weerasuriya, D. K., Quon, A., Quynh-Thu Le, Q. T., … Loo, B. W. (2012). Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 13(1), 52–58.

Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer
Das, M., Donington, J. S., Murphy, J., Kozak, M., Eclov, N., Whyte, R. I., … Wakelee, H. (2011). Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 12(5), 280–85.

Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer
Kozak, M. M., Murphy, J. D., Schipper, M. L., Donington, J. S., Zhou, L., Whyte, R. I., … Loo, B. W. (2011). Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 6(5), 920–26.

Angiogenesis Inhibitors
Das, M., & Wakelee, H. (2011). Angiogenesis Inhibitors. JOURNAL OF THORACIC ONCOLOGY, 6(11), S1801–S1802.

XL647-A Multitargeted Tyrosine Kinase Inhibitor Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib
Pietanza, M. C., Lynch, T. J., Lara, P. N., Cho, J., Yanagihara, R. H., Vrindavanam, N., … Miller, V. A. (2012). XL647-A Multitargeted Tyrosine Kinase Inhibitor Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib. JOURNAL OF THORACIC ONCOLOGY, 7(1), 219–26.

Current Management of Small Cell Lung Cancer
Neal, J. W., Gubens, M. A., & Wakelee, H. A. (2011). Current Management of Small Cell Lung Cancer. CLINICS IN CHEST MEDICINE, 32(4), 853-?

A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
Rodon, J., Jacobs, C. D., Chu, Q., Rowinsky, E. K., Lopez-Anaya, A., Takimoto, C. H., & Wakelee, H. A. (2012). A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(3), 825–34.

A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Wakelee, H. A., Middleton, G., Dunlop, D., Ramlau, R., Leighl, N., Hao, D., … Jacobs, C. D. (2012). A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(3), 815–24.

The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer
Wakelee, H. A., Takimoto, C. H., Lopez-Anaya, A., Chu, Q., Middleton, G., Dunlop, D., … Rodon, J. (2012). The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(2), 563–71.

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., Pedro-Salcedo, M. S., … Wakelee, H. A. (2012). A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(4), 1013–20.

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab
Wakelee, H. A., DAHLBERG, S. E., Brahmer, J. R., Schiller, J. H., Perry, M. C., Langer, C. J., … Johnson, D. H. (2012). Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. LUNG CANCER, 76(3), 410–15.

Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer
Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., Ganjoo, K., … Wakelee, H. A. (2012). Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer. CANCER INVESTIGATION, 30(3), 231–35.

Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
Trakul, N., Chang, C. N., Harris, J., Chapman, C., Rao, A., Shen, J., … Diehn, M. (2012). Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(1), 231–37.

Targeting VEGF in lung cancer
Das, M., & Wakelee, H. (2012). Targeting VEGF in lung cancer. EXPERT OPINION ON THERAPEUTIC TARGETS, 16(4), 395–406.

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
Das, M., Riess, J. W., Frankel, P., Schwartz, E., Bennis, R., Hsieh, H. B., … Bruce, R. H. (2012). ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer , 77(2), 421–26.

Adjuvant chemotherapy for early stage non-small cell lung cancer.
Patel, M. I., & Wakelee, H. A. (2011). Adjuvant chemotherapy for early stage non-small cell lung cancer. Frontiers in Oncology, 1, 45-?

Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess, J. W., & Wakelee, H. A. (2012). Metastatic non-small cell lung cancer management: novel targets and recent clinical advances. Clinical Advances in Hematology & Oncology : H&O, 10(4), 226–34.

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. R. A., Colevas, A. D., Shepherd, F. A., … Wakelee, H. A. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. BRITISH JOURNAL OF CANCER, 107(4), 604–11.

A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer
Clement-Duchene, C., Natale, R. B., Jahan, T., Krupitskaya, Y., Osarogiagbon, R., Sanborn, R. E., … Wakelee, H. A. (2012). A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. LUNG CANCER, 78(1), 57–62.

Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge
Nagpal, S., Riess, J., & Wakelee, H. (2012). Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 13(4), 491–504.

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients Eastern Cooperative Oncology Group Study E2501
Wakelee, H. A., Lee, J.-W., Hanna, N. H., Traynor, A. M., Carbone, D. P., & Schiller, J. H. (2012). A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients Eastern Cooperative Oncology Group Study E2501. JOURNAL OF THORACIC ONCOLOGY, 7(10), 1574–82.

Angiogenesis inhibitors.
Das, M., & Wakelee, H. (2012). Angiogenesis inhibitors. Journal of Thoracic Oncology , 7(16), S397–8.

Aflibercept in lung cancer
Neal, J. W., & Wakelee, H. A. (2013). Aflibercept in lung cancer. EXPERT OPINION ON BIOLOGICAL THERAPY, 13(1), 115–20.

A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Journal of Thoracic Oncology , 8(2), e17–8.

Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Padda, S. K., Chhatwani, L., Zhou, L., Jacobs, C. D., Lopez-Anaya, A., & Wakelee, H. A. (2013). Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report. Anti-Cancer Drugs, 24(7), 731–35.

A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
Riess, J. W., Nagpal, S., Neal, J. W., & Wake, H. A. (2013). A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(4), 389–94.

Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines
HAWS, C. M., Nepomuceno, I. B., Krouse, M. E., Wakelee, H., Law, T., Xia, Y., … Wine, J. J. (1996). Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 270(5), C1544–C1555.

Estrogen Alone and Lung Cancer in Postmenopausal Women
Chlebowski, R., Anderson, G., Manson, J., Schwartz, A., Wakelee, H., Gass, M., … Stefanick, M. (2010). Estrogen Alone and Lung Cancer in Postmenopausal Women. GYNECOLOGIC ONCOLOGY, 117(2), 394–94.

Quantification of pre-treatment metabolic tumor growth rate in lung cancer
Eastham, D., Chapman, C. H., Rao, A. K., Balasubramanian, N., Quon, A., Vasanawala, M. S., … Loo, B. W. (2009). Quantification of pre-treatment metabolic tumor growth rate in lung cancer. JOURNAL OF THORACIC ONCOLOGY, 4(9), S733–S733.

Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?
Eastham, D. V., Chapman, C. H., Rao, A. K., Narasimhan, B., Quon, A., Vasanawala, M. S., … Loo, B. W. (2009). Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S446–S446.

Single fraction stereotactic radiosurgery (SFSR) for lung tumors - A phase I dose escalation trial.
Le, Q. T., Ho, A., Cotrutz, C., Wakelee, H., Kee, S. T., Donington, I., & Whyte, R. I. (2004). Single fraction stereotactic radiosurgery (SFSR) for lung tumors - A phase I dose escalation trial. JOURNAL OF CLINICAL ONCOLOGY, 22(14), 673S–673S.

Changes in FDG-PET/CT Parameters on Serial Pre-radiotherapy Scans Predict Disease Progression and Survival in Patients with Non-small Cell Lung Cancer
Bazan, J. G., Chung, M. P., Eastham, D. V., Wakelee, H., Hara, W. Y., Maxim, P. G., … Loo, B. W. (2011). Changes in FDG-PET/CT Parameters on Serial Pre-radiotherapy Scans Predict Disease Progression and Survival in Patients with Non-small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S579–S580.

A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies
Wakelee, H., Adjei, A. A., Keer, H., Halsey, J., Hanson, L., Reid, J., … Sikic, B. I. (2005). A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 227S–227S.

MAINTENANCE BEVACIZUMAB MONOTHERAPY INCREASES HEMOGLOBIN (HGB) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG ADENOCARCINOMA (NSCLC-AD)
Riess, J. W., Logan, A., Krupitskaya, Y., Clement-Duchene, C., Kuo, C., & Wakelee, H. (2011). MAINTENANCE BEVACIZUMAB MONOTHERAPY INCREASES HEMOGLOBIN (HGB) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG ADENOCARCINOMA (NSCLC-AD). JOURNAL OF THORACIC ONCOLOGY, 6(6), S962–S963.

Systemic VEGF Inhibition Induces Hepatic EPO Production and Erythrocytosis Via HIF-2a-Dependent and -Independent Mechanisms
Wei, K., Logan, A. C., Wakelee, H., Simon, M. C., & Kuo, C. J. (2008). Systemic VEGF Inhibition Induces Hepatic EPO Production and Erythrocytosis Via HIF-2a-Dependent and -Independent Mechanisms. BLOOD, 112(11), 183–84.

Tumor size is a critical determinant of local control in single fraction stereotactic radiotherapy of pulmonary tumors
Loo, B. W., Shen, J., Quinlan-Davidson, S., Filion, E., Dieterich, S., Maxim, P. G., … Le, Q. (2008). Tumor size is a critical determinant of local control in single fraction stereotactic radiotherapy of pulmonary tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S467–S468.

Mid-treatment PET predicts progression in hypofractionated accelerated radiation therapy for lung tumors
Chang, C. N., Fillion, E., Chapman, C., Rao, A., Wakelee, H., Ganjoo, K., … Loo, B. W. (2009). Mid-treatment PET predicts progression in hypofractionated accelerated radiation therapy for lung tumors. JOURNAL OF THORACIC ONCOLOGY, 4(9), S939–S939.

Excellent early local control with tumor volume adapted dosing of stereotactic body radiation therapy for pulmonary tumors
Chang, C. N., Zhou, L. Y., MacFarlane, G., Tran, P., Rao, A., Chapman, C., … Loo, B. W. (2009). Excellent early local control with tumor volume adapted dosing of stereotactic body radiation therapy for pulmonary tumors. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies
Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzgerald, A. M., & Sikic, B. (2005). A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 234S–234S.

Correlation of ERCC1 expression on circulating tumor cells with progression-free survival in metastatic non-small cell lung cancer patients treated with platinum-based chemotherapy
Riess, J., Das, M. S., Frankel, P. H., Schwartz, E., Bennis, R., Ben Hsieh, H., … Wakelee, H. A. (2012). Correlation of ERCC1 expression on circulating tumor cells with progression-free survival in metastatic non-small cell lung cancer patients treated with platinum-based chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. CHICAGO,IL,IL,IL: AMER SOC CLINICAL ONCOLOGY.

How Do Social Factors Explain Outcomes In Non-small Cell Lung Cancer Among Hispanic/latinos In California?
Patel, M. I., Chang, E., Gomez, S., & Wakelee, H. A. (2012). How Do Social Factors Explain Outcomes In Non-small Cell Lung Cancer Among Hispanic/latinos In California? JOURNAL OF THORACIC ONCOLOGY, 7(9), S216–S216.

How do social factors explain outcomes in non-small cell lung cancer among Hispanics/Latinos in California?
Patel, M. I., Chang, E. T., Gomez, S. L., Schupp, C., & Wakelee, H. A. (2012). How do social factors explain outcomes in non-small cell lung cancer among Hispanics/Latinos in California? JOURNAL OF CLINICAL ONCOLOGY, 30(15).

Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Neal, J. W., & Wakelee, H. A. (2012). Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

A Quantitative Assay of ERCC1 Expression in Circulating Tumor Cells (CTCs) in Non-small Cell Lung Cancer (NSCLC): A Potential Predictor of Treatment Response
Das, M., Hsieh, B. H., Krivacic, R. T., Lazarus, N., Bennis, R., Ly, J., … Wakelee, H. A. (2010). A Quantitative Assay of ERCC1 Expression in Circulating Tumor Cells (CTCs) in Non-small Cell Lung Cancer (NSCLC): A Potential Predictor of Treatment Response. JOURNAL OF THORACIC ONCOLOGY, 5(12), S535–S535.

Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study
Das, M., & Wakelee, H. (2012). Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study. JOURNAL OF THORACIC DISEASE, 4(6), 558–61.

A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., … Wakelee, H. A. (2012). A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 30(15).

A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.
Fishe, G. A., Kuo, T., Cho, C. D., Halsey, J., Jambalos, C. N., Schwartz, E. J., … Wakelee, H. A. (2004). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22(14), 248S–248S.

A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.
Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., Rouse, R. V., … Sikic, B. I. (2003). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. CLINICAL CANCER RESEARCH, 9(16), 6103S–6103S.

A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC)
Krupitskaya, Y., Ganjoo, K., Lavori, P. W., Kumar, A., Clement-Duchene, C., Zhao, G., … Wakelee, H. A. (2009). A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 27(15).

A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., Kumar, A., Zhao, G., … Wakelee, H. (2009). A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 4(9), S674–S674.

A single arm phase 2 study of enzastaurin in combination with erlotinib, both administered orally daily, to patients with advanced non-small cell lung cancer (NSCLC)
Wakelee, H. A., Dubey, S., Krupitskaya, Y., Osarogiagbon, R. U., Sanborn, R. E., Bernstein, E. D., … Natale, R. B. (2009). A single arm phase 2 study of enzastaurin in combination with erlotinib, both administered orally daily, to patients with advanced non-small cell lung cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 4(9), S445–S445.

Results of a phase I dose escalation study using single fraction stereotactic radiosurgery (SFSR) for lung tumors
Le, Q. X., Ho, A., Cotrutz, C., Loo, B., Petrik, D., Wakelee, H., … Donington, J. S. (2005). Results of a phase I dose escalation study using single fraction stereotactic radiosurgery (SFSR) for lung tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(2), S226–S226.

A Phase II Study Of Saracatinib (AZD0530), A Src Inhibitor, Administered Orally Daily To Patients With Advanced Thymic Malignancies
Wakelee, H. A., Gubens, M. A., Burns, M., Barbeau, S. L., Perkins, S., Pedo-Salcedo, M. G. S., & Loehrer, P. J. (2010). A Phase II Study Of Saracatinib (AZD0530), A Src Inhibitor, Administered Orally Daily To Patients With Advanced Thymic Malignancies. JOURNAL OF THORACIC ONCOLOGY, 5(12), S528–S528.

A phase 1 dose-escalation and pharmacokinetic (PK) study of a novel spectrum-selective kinase inhibitor (SSKI), XL647, in patients with advanced solid malignancies.
Wakelee, H., Adjei, A. A., Halsey, J., Lensing, J., Dugay, J., Hanson, L., … Sikic, B. I. (2005). A phase 1 dose-escalation and pharmacokinetic (PK) study of a novel spectrum-selective kinase inhibitor (SSKI), XL647, in patients with advanced solid malignancies. CLINICAL CANCER RESEARCH, 11(24), 9029S–9029S.

A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM)
Sikic, B. I., Wakelee, H. A., Adjei, A. A., Halsey, J., Lensing, J. L., Dugay, J. D., … Piens, J. R. (2006). A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM). EJC SUPPLEMENTS, 4(12), 106–7.

A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM).
Wakelee, H. A., Adjei, A. A., Halsey, J., Lensing, J. L., Dugay, J. D., Hanson, L. J., … Sikic, B. I. (2006). A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). JOURNAL OF CLINICAL ONCOLOGY, 24(18), 131S–131S.

Effect of bexarotene on vinorelbine and cisplatin pharmacokinetics during a Phase I study in patients with advanced non-small cell lung cancer (NSCLC)
Wakelee, H., Middleton, G., Dunlop, D., Kelly, C., Ramlau, R., Leighl, N., … Loewen, G. (2005). Effect of bexarotene on vinorelbine and cisplatin pharmacokinetics during a Phase I study in patients with advanced non-small cell lung cancer (NSCLC). Presented at the 11th World Conference on Lung Cancer, BARCELONA,SPAIN,SPAIN: ELSEVIER IRELAND LTD.

A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements.
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., Adrouny, A. R., … Wakelee, H. A. (2013). A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. Clinical Lung Cancer, 14(5), 592–95.

miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma
Xu, Y., Zheng, M., Merritt, R. E., Shrager, J. B., Wakelee, H. A., Kratzke, R. A., & Hoang, C. D. (2013). miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma. CHEST, 144(5), 1632–43.

Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial
Chlebowski, R. T., Schwartz, A., Wakelee, H., Anderson, G. L., Stefanick, M. L., Manson, J. E., … Gass, M. (2009). Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial. JOURNAL OF CLINICAL ONCOLOGY, 27(15).

Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial
Chlebowski, R. T., Schwartz, A., Wakelee, H., Anderson, G. L., Stefanick, M. L., Manson, J. E., … Gass, M. (2009). Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial. JOURNAL OF CLINICAL ONCOLOGY, 27(18).

How do social factors explain outcomes in non-small-cell lung cancer among Hispanics in California? Explaining the Hispanic paradox.
Patel, M. I., Schupp, C. W., Gomez, S. L., Chang, E. T., & Wakelee, H. A. (2013). How do social factors explain outcomes in non-small-cell lung cancer among Hispanics in California? Explaining the Hispanic paradox. Journal of Clinical Oncology , 31(28), 3572–78.

How do social factors explain outcomes in non-small-cell lung cancer among hispanics in california? Explaining the Hispanic paradox.
Patel, M. I., Schupp, C. W., Gomez, S. L., Chang, E. T., & Wakelee, H. A. (2013). How do social factors explain outcomes in non-small-cell lung cancer among hispanics in california? Explaining the Hispanic paradox. Journal of Clinical Oncology , 31(28), 3572–3578.

Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., … Wang, S. X. (2013). Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab on a Chip, 14(1), 78–88.

Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., … Wakelee, H. A. (2014). Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clinical Lung Cancer, 15(3), 202–6.

Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., … Wang, S. X. (2014). Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. LAB ON A CHIP, 14(1), 78–88.

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., … Wakelee, H. A. (2014). A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. British Journal of Cancer, 110(3), 602–8.

Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy.
Padda, S. K., Burt, B. M., Trakul, N., & Wakelee, H. A. (2014). Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. Seminars in Oncology, 41(1), 40–56.

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., … Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 20(5), 548–54.

Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.
Riess, J. W., Bhattacharya, N., Blenman, K. R. M., Neal, J. W., Hwang, G., Pultar, P., … Wakelee, H. A. (2014). Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacology and Immunotoxicology, 36(2), 182–86.

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., … Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. NATURE MEDICINE, 20(5), 552–58.

A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab. JOURNAL OF THORACIC ONCOLOGY, 8(2), E17–E18.

Response.
Xu, Y., Zheng, M., Khuong, A., Merritt, R. E., Shrager, J. B., Wakelee, H. A., … Hoang, C. D. (2013). Response. Chest, 144(6), 1971–72.

Lung Cancer Incidence Trends by Histology Type among Asian American, Native Hawaiian, and Pacific Islander Populations in the United States, 1990-2010
Cheng, I., Le, G. M., Noone, A.-M., Gali, K., Patel, M., Haile, R. W., … Gomez, S. L. (2014). Lung Cancer Incidence Trends by Histology Type among Asian American, Native Hawaiian, and Pacific Islander Populations in the United States, 1990-2010. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 23(11), 2250–65.

Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort†.
Wang, A., Kubo, J., Luo, J., Desai, M., Hedlin, H., Henderson, M., … Wakelee, H. A. (2015). Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort†. Annals of Oncology , 26(1), 221–30.

Review of the current targeted therapies for non-small-cell lung cancer.
Nguyen, K.-S. H., Neal, J. W., & Wakelee, H. (2014). Review of the current targeted therapies for non-small-cell lung cancer. World Journal of Clinical Oncology, 5(4), 576–87.

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.
Liang, Y., Padda, S. K., Riess, J. W., West, R. B., Neal, J. W., & Wakelee, H. A. (2015). Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer , 87(1), 34–38.

GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., & Wakelee, H. A. (2015). GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. Anticancer Research, 35(2), 669–76.

Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors.
Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., … Wakelee, H. A. (2015). Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors. Journal of Thoracic Oncology , 10(3), 500–508.

Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC.
Das, M., & Wakelee, H. (2014). Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC. Translational Lung Cancer Research, 3(6), 397–99.

MET inhibitors in combination with other therapies in non-small cell lung cancer.
Padda, S., Neal, J. W., & Wakelee, H. A. (2012). MET inhibitors in combination with other therapies in non-small cell lung cancer. Translational Lung Cancer Research, 1(4), 238–53.

Hormone Use, Reproductive History, and Risk of Lung Cancer The Women's Health Initiative Studies
Schwartz, A. G., Ray, R. M., Cote, M. L., Abrams, J., Sokol, R. J., Hendrix, S. L., … Simon, M. S. (2015). Hormone Use, Reproductive History, and Risk of Lung Cancer The Women's Health Initiative Studies. JOURNAL OF THORACIC ONCOLOGY, 10(7), 1004–13.

Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., … Camidge, D. R. (2015). Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 372(18), 1700–1709.

[Chemotherapy definitions and policies for thymic malignancies].
Girard, N., Lal, R., Wakelee, H., Riely, G. J., & Loehrer, P. J. (2014). [Chemotherapy definitions and policies for thymic malignancies]. Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 17(2), 116–21.

Chemotherapy Definitions and Policies for Thymic Malignancies
Girard, N., Lal, R., Wakelee, H., Riely, G. J., & Loehrer, P. J. (2011). Chemotherapy Definitions and Policies for Thymic Malignancies. JOURNAL OF THORACIC ONCOLOGY, 6(7), S1749–S1755.

Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors
Huang, J., Ahmad, U., Antonicelli, A., Catlin, A. C., Fang, W., Gomez, D., … Detterbeck, F. (2014). Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors. JOURNAL OF THORACIC ONCOLOGY, 9(10), 1573–78.

A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies
Gubens, M. A., Burns, M., Perkins, S. M., Pedro-Salcedo, M. S., Althouse, S. K., Loehrer, P. J., & Wakelee, H. A. (2015). A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. LUNG CANCER, 89(1), 57–60.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., … Sequist, L. V. (2015). Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 5(7), 713–22.

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015). Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. LUNG CANCER, 89(3), 280–86.

Incidence Trends of Lung Cancer by Immigration Status among Chinese Americans
Gomez, S. L., Yang, J., Lin, S.-W., McCusker, M., Sandler, A., Cheng, I., … Clarke, C. A. (2015). Incidence Trends of Lung Cancer by Immigration Status among Chinese Americans. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 24(8), 1157–64.

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer
Liang, Y., Wakelee, H. A., & Neal, J. W. (2015). Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 16(5), 366–73.

Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang, J. C., Neal, J. W., Niu, X.-M., & Wakelee, H. A. (2015). Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. Lung Cancer , 90(1), 1–7.

Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Leung, L.-S. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., & Marmor, M. F. (2015). Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. American Journal of Ophthalmology, 160(4), 799–805 e1.

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
Paz-Ares, L., Hirsh, V., Zhang, L., De Marinis, F., Yang, J. C.-H., Wakelee, H. A., … Mok, T. S. (2015). Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. JOURNAL OF THORACIC ONCOLOGY, 10(12), 1745–53.

Pruritus as a Paraneoplastic Symptom of Thymoma
Padda, S. K., Shrager, J. B., Riess, J. W., Pagtama, J. Y., Tisch, A. J. H., Kwong, B. Y., … Wakelee, H. A. (2015). Pruritus as a Paraneoplastic Symptom of Thymoma. JOURNAL OF THORACIC ONCOLOGY, 10(11), E110–E112.

Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Leung, L.-S. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., & Marmor, M. F. (2015). Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. American Journal of Ophthalmology, 160(4), 799–805 e1.

Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial
Chlebowski, R. T., Wakelee, H., Pettinger, M., Rohan, T., Liu, J., Simon, M., … Wactawski-Wende, J. (2016). Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. CLINICAL LUNG CANCER, 17(1), 10-?

Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
Myall, N. J., Neal, J. W., Cho-Phan, C. D., Zhou, L. Y., Stehr, H., Zhou, L., … Wakelee, H. A. (2016). Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. Clinical Lung Cancer, 17(2), e17–21.

Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.
Schaberg, K. B., Novoa, R. A., Wakelee, H. A., Kim, J., Cheung, C., Srinivas, S., & Kwong, B. Y. (2016). Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. Journal of Cutaneous Pathology, 43(4), 339–46.

Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., … Alizadeh, A. A. (2016). Integrated digital error suppression for improved detection of circulating tumor DNA. NATURE BIOTECHNOLOGY, 34(5), 547–55.

Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative.
Patel, M. I., Wang, A., Kapphahn, K., Desai, M., Chlebowski, R. T., Simon, M. S., … Wakelee, H. A. (2016). Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative. Journal of Clinical Oncology , 34(4), 360–68.

Survival among Never-Smokers with Lung Cancer in the Cancer Care Outcomes Research and Surveillance Study.
Clément-Duchêne, C., Stock, S., Xu, X., Chang, E. T., Gomez, S. L., West, D. W., … Gould, M. K. (2016). Survival among Never-Smokers with Lung Cancer in the Cancer Care Outcomes Research and Surveillance Study. Annals of the American Thoracic Society, 13(1), 58–66.

Association of non-melanoma skin cancer with second non-cutaneous malignancy in the Women's Health Initiative.
Ransohoff, K. J., Stefanick, M. L., Li, S., Kurian, A. W., Wakelee, H., Wang, A., … Tang, J. Y. (2016). Association of non-melanoma skin cancer with second non-cutaneous malignancy in the Women's Health Initiative. The British Journal of Dermatology.

Statin use and all-cancer survival: prospective results from the Women's Health Initiative
Wang, A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. A. E., Chlebowski, R. T., … Stefanick, M. L. (2016). Statin use and all-cancer survival: prospective results from the Women's Health Initiative. BRITISH JOURNAL OF CANCER, 115(1), 129–35.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., … Diehn, M. (2016). Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. NATURE COMMUNICATIONS, 7.

ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
Guerin, A., Sasane, M., Zhang, J., Macalalad, A. R., Galebach, P., Jarvis, J., … Wakelee, H. (2015). ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. CANCER EPIDEMIOLOGY, 39(3), 307–12.

Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative.
Wang, A., Qin, F., Hedlin, H., Desai, M., Chlebowski, R., Gomez, S., … Stefanick, M. L. (2016). Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative. International Journal of Cancer, 139(10), 2178–92.

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Karlovich, C., Goldman, J. W., Sun, J.-M., Mann, E., Sequist, L. V., Konopa, K., … Wakelee, H. (2016). Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). CLINICAL CANCER RESEARCH, 22(10), 2386–95.

Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions
Chuang, J. C., Salahudeen, A. A., & Wakelee, H. A. (2016). Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions. EXPERT OPINION ON PHARMACOTHERAPY, 17(7), 989–93.

Scientific Advances in Lung Cancer 2015
Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., … Pass, H. I. (2016). Scientific Advances in Lung Cancer 2015. JOURNAL OF THORACIC ONCOLOGY, 11(5), 613–38.

Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.
Chuang, J. C., Shrager, J. B., Wakelee, H. A., & Neal, J. W. (2016). Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. Clinical Therapeutics, 38(7), 1567–76.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization
Ali, S. M., Hensing, T., Schrock, A. B., Allen, J., Sanford, E., Gowen, K., … Salgia, R. (2016). Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. ONCOLOGIST, 21(6), 762–70.

Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer With T790M Mutations
Castellanos, E. H., Rivera, G., Wakelee, H., & Horn, L. (2015). Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer With T790M Mutations. CLINICAL LUNG CANCER, 16(5), E97–E99.

Are Patients With Thoracic Malignancies at Risk for Uncontrolled Symptoms?
Patel, M. I., Williams, D. C., Wohlforth, C., Fisher, G., Wakelee, H. A., & Blayney, D. W. (2015). Are Patients With Thoracic Malignancies at Risk for Uncontrolled Symptoms? Journal of Oncology Practice / American Society of Clinical Oncology, 11(1), e98–e102.

Lung Cancer in Never Smokers.
Rivera, G. A., & Wakelee, H. (2016). Lung Cancer in Never Smokers. Advances in Experimental Medicine and Biology, 893, 43–57.

Resistance to Therapy.
Rivera, G., & Wakelee, H. A. (2016). Resistance to Therapy. Cancer Treatment and Research, 170, 183–202.

Pretreatment biopsy for thymic epithelial tumors-does histology subtype matter for treatment strategy?
Padda, S. K., Keijzers, M., & Wakelee, H. A. (2016). Pretreatment biopsy for thymic epithelial tumors-does histology subtype matter for treatment strategy? Journal of Thoracic Disease, 8(8), 1895–1900.

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Crinò, L., Ahn, M.-J., De Marinis, F., Groen, H. J. M., Wakelee, H., Hida, T., … Shaw, A. T. (2016). Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. Journal of Clinical Oncology , 34(24), 2866–73.

Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?
Wang, A., Wakelee, H. A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. A. E., & Stefanick, M. L. (2016). Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients? Current Atherosclerosis Reports, 18(12), 72-?

Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy
Guerin, A., Sasane, M., Wakelee, H., Zhang, J., Culver, K., Dea, K., … Macalalad, A. R. (2015). Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy. CURRENT MEDICAL RESEARCH AND OPINION, 31(8), 1587–97.

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
Reckamp, K. L., Melnikova, V. O., Karlovich, C., Sequist, L. V., Camidge, D. R., Wakelee, H., … Gadgeel, S. (2016). A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. Journal of Thoracic Oncology , 11(10), 1690–1700.

Diagnosis in oncology - Lung cancer presenting with amegakaryocytic thrombocytopenia
Witteles, W. H., Schrier, S. L., & Wakelee, H. A. (2008). Diagnosis in oncology - Lung cancer presenting with amegakaryocytic thrombocytopenia. JOURNAL OF CLINICAL ONCOLOGY, 26(7), 1171–74.

GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray.
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., & Wakelee, H. A. (2015). GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray. Anticancer Research, 35(2), 669–76.

Clinicopathologic Features of Advanced Squamous NSCLC.
Socinski, M. A., Obasaju, C., Gandara, D., Hirsch, F. R., Bonomi, P., Bunn, P., … Thatcher, N. (2016). Clinicopathologic Features of Advanced Squamous NSCLC. Journal of Thoracic Oncology , 11(9), 1411–22.

Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'.
Wang, A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. A. E., Chlebowski, R. T., … Stefanick, M. L. (2017). Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'. British Journal of Cancer, 116(3).

Molecular profiling of single circulating tumor cells from lung cancer patients
Park, S.-M., Wong, D. J., Ooi, C. C., Kurtz, D. M., Vermesh, O., Aalipour, A., … Gambhir, S. S. (2016). Molecular profiling of single circulating tumor cells from lung cancer patients. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113(52), E8379–E8386.

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy
Das, M., Riess, J. W., Frankel, P., Schwartz, E., Bennis, R., Ben Hsieh, H., … Bruce, R. H. (2012). ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. LUNG CANCER, 77(2), 421–26.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.
Langer, C. J., Obasaju, C., Bunn, P., Bonomi, P., Gandara, D., Hirsch, F. R., … Thatcher, N. (2016). Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. Journal of Thoracic Oncology .

The Burden of Cancer in Asian Americans: A Report of National Mortality Trends by Asian Ethnicity
Thompson, C. A., Gomez, S. L., Hastings, K. G., Kapphahn, K., Yu, P., Shariff-Marco, S., … Palaniappan, L. P. (2016). The Burden of Cancer in Asian Americans: A Report of National Mortality Trends by Asian Ethnicity. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 25(10), 1371–82.

Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry.
Burt, B. M., Yao, X., Shrager, J., Antonicelli, A., Padda, S., Reiss, J., … Scott, W. (2016). Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry. Journal of Thoracic Oncology .

Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative
Bastian, L. A., Gray, K. E., Derycke, E., Mirza, S., Gierisch, J. M., Haskell, S. G., … LaCroix, A. Z. (2016). Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative. GERONTOLOGIST, 56, S102–S111.

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.
Salahudeen, A. A., Patel, M. I., Baas, P., Curran, W. J., Bradley, J. D., Gandara, D. R., … Wakelee, H. A. (2017). Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. Clinical Lung Cancer, 18(1), 5–12.

Adding to the targeted therapy toolbox: BRAF and MEK inhibition in the treatment of BRAF V600E metastatic non-small cell lung cancer
Myall, N. J., & Wakelee, H. A. (2016). Adding to the targeted therapy toolbox: BRAF and MEK inhibition in the treatment of BRAF V600E metastatic non-small cell lung cancer. TRANSLATIONAL CANCER RESEARCH, 5, S1233–S1240.

Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry
Burt, B. M., Yao, X., Shrager, J., Antonicelli, A., Padda, S., Reiss, J., … Scott, W. (2017). Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry. JOURNAL OF THORACIC ONCOLOGY, 12(1), 129–36.

PS01.22: Novel 3-Dimensional Preclinical Models: Topic: Medical Oncology.
Salahudeen, A., De La O, S., Padda, S. K., Neal, J. W., Wakelee, H., & Kuo, C. (2016). PS01.22: Novel 3-Dimensional Preclinical Models: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S282-?

PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology.
Neal, J. W., Wakelee, H., Padda, S. K., Bertrand, S., Acevedo, B., Holmes Tisch, A., … Nagpal, S. (2016). PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S271–S272.

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Chuang, J. C., Stehr, H., Liang, Y., Das, M., Huang, J., Diehn, M., … Neal, J. W. (2017). ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. Journal of Thoracic Oncology .

ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology.
Wakelee, H., Patel, J. D., Heist, R., Balmanoukian, A., Besse, B., Felip, E., … Peters, S. (2016). ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S251–S252.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., … Diehn, M. (2016). Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 7, 13513-?

PS01.77: Risk-Stratification for Second Primary Lung Cancer: Topic: Medical Oncology.
Han, S., Rivera, G. A., Cheng, I., Gomez, S., Plevritis, S. K., & Wakelee, H. (2016). PS01.77: Risk-Stratification for Second Primary Lung Cancer: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S319–S320.

Elusive Target of Angiogenesis in Small-Cell Lung Cancer.
Neal, J. W., & Wakelee, H. A. (2017). Elusive Target of Angiogenesis in Small-Cell Lung Cancer. Journal of Clinical Oncology , JCO2016716084-?

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., … Ramalingam, S. S. (2016). Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. LANCET ONCOLOGY, 17(12), 1661–71.

MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens.
Paz-Ares, L., Hirsh, V., Zhang, L., De Marinis, F., Yang, J. C. H., Wakelee, H. A., … Mok, T. S. (2015). MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens. Journal of Thoracic Oncology , -?

Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer
Chuang, J. C., Liang, Y., & Wakelee, H. A. (2017). Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 31(1), 31-?

Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis.
Gubens, M. A., & Wakelee, H. A. (2010). Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis. Lung Cancer (Auckland, N.Z.), 1, 63–76.

PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology.
Vallieres, E., Felip, E., Altorki, N., Zhou, C., Zuo, Y., Howland, M., … Wakelee, H. (2016). PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S304-?

PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC: Topic: Medical Oncology.
Wakelee, H., Goldman, J. W., Gadgeel, S., Camidge, D. R., Reckamp, K. L., Ou, S.-H. I., … Carbone, D. (2016). PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S311–S312.

PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology.
Wang, S. X., Zhang, B. M., Wakelee, H., Diehn, M., Kunder, C. A., & Neal, J. W. (2016). PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S312–S313.

MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology.
Horn, L., Wakelee, H., Reckamp, K. L., Blumenschein, G., Infante, J. R., Carter, C. A., … Lovly, C. M. (2016). MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S256–S257.

Novel Treatments for Thymoma and Thymic Carcinoma.
Rajan, A., Wakelee, H., & Giaccone, G. (2015). Novel Treatments for Thymoma and Thymic Carcinoma. Frontiers in Oncology, 5, 267-?

-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
Baik, C. S., Myall, N. J., & Wakelee, H. A. (2017). -Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy. Oncologist.

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
Wakelee, H. A., Gettinger, S., Engelman, J., Janne, P. A., West, H., Subramaniam, D. S., … Lara, P. N. (2017). A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 79(5), 923–32.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., … Drilon, A. (2017). Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. JOURNAL OF CLINICAL ONCOLOGY, 35(13), 1403-?

Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non Small-Cell Lung Cancer
Wakelee, H., Zvirbule, Z., de Braud, F., Kingsley, C. D., Mekhail, T., Lowe, T., … Novello, S. (2017). Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 18(1), 50–59.

Scientific Advances in Thoracic Oncology 2016.
Soo, R. A., Stone, E. C., Cummings, K. M., Jett, J. R., Field, J. K., Groen, H. J. M., … Spigel, D. R. (2017). Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology .

-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
Baik, C. S., Myall, N. J., & Wakelee, H. A. (2017). -Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy. Oncologist.

Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib.
Wang, S. X., Zhang, B., Wakelee, H. A., Diehn, M., Kunder, C., & Neal, J. W. (2017). Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib. International Journal of Radiation Oncology, Biology, Physics, 98(1), 239-?

Chart Review Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer
Bui, N., Henry, S., Wood, D., Wakelee, H. A., & Neal, J. W. (2017). Chart Review Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer. JCO: Clinical Cancer Informatics.

Monitoring Neutropenia for Cancer Patients at the Point of Care
Inan, H. (2017). Monitoring Neutropenia for Cancer Patients at the Point of Care. Small Methods.

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Choi, C. Y., Wakelee, H. A., Neal, J. W., Pinder-Schenck, M. C., Yu, H.-H. M., Chang, S. D., … Soltys, S. G. (2017). Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. International Journal of Radiation Oncology, Biology, Physics, 99(1), 16–21.

Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery.

The CD47 Macrophage Checkpoint as a New Immunotherapy Target
Sikic, B. I., Padda, S. K., Shah, S. A., Colevas, D., Narayanan, S., Fisher, G. A., … Weissman, I. L. (2017). The CD47 Macrophage Checkpoint as a New Immunotherapy Target. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A., Stehr, H., Azad, T. D., … Diehn, M. (2017). Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), S114.

Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing
Diehn, M., Bratman, S. V., Newman, A. M., Neal, J. W., Wakelee, H. A., Merritt, R. E., … Alizadeh, A. (2014). Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S75.

Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Merriott, D. J., … Diehn, M. (2017). Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), S1–S2.

Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC
Modlin, L. A., Bratman, S. V., Newman, A. M., Eclov, N. C. W., Neal, J. W., Wakelee, H. A., … Diehn, M. (2014). Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S812.

CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Say, C., … Diehn, M. (2016). CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 96(2), S41–S42.

Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer
Chaudhuri, A., Lovejoy, A., Chabon, J., Newman, A., Stehr, H., Say, C., … Diehn, M. (2017). Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 12(1), S445.

Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer
Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., … Diehn, M. (2017). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), S20–S21.

Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing
Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H., … Diehn, M. (2013). Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S92.

Racial/Ethnic Variations in Lung Cancer Incidence and Mortality, Adjusted for Smoking Behavior: Results From the Women's Health Initiative
Patel, M. I., Wang, A., Kapphahn, K., Kubo, J., Desai, M., Chlebowski, R., … Wakelee, H. (2014). Racial/Ethnic Variations in Lung Cancer Incidence and Mortality, Adjusted for Smoking Behavior: Results From the Women's Health Initiative. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

COPD and risk of lung cancer in post-menopausal women: findings from the Women's Health Initiative
Cote, M. L., Lehman, A., Chlebowski, R., Haynes, B., Ho, G., Patel, M., … Schwartz, A. (2015). COPD and risk of lung cancer in post-menopausal women: findings from the Women's Health Initiative. CANCER RESEARCH, 75.

Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy.
Shukla, N. D., Salahudeen, A. A., Taylor, G. A., Ramalingam, S. S., Vokes, E. E., Goss, G. D., … Wakelee, H. A. (2018). Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. Clinical Lung Cancer.

Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative prospective cohort study.
Wang, A., Kubo, J., Luo, J., Desai, M., Henderson, M. T., Chlebowski, R. T., … Wakelee, H. A. (2013). Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative prospective cohort study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Circulating tumor DNA testing in advanced non-small cell lung cancer.
Moding, E. J., Diehn, M., & Wakelee, H. A. (2018). Circulating tumor DNA testing in advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 119, 42–47.

Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non-small Cell Lung Cancer
Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C. N., Eclov, N., To, J., Murphy, J. D., … Loo, B. W. (2017). Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non-small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), E456.

Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers
Gautschi, O., Milia-Baron, J., Filleron, T., Wolf, J., Carbone, D., Owen, D., … Drilon, A. (2017). Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Y Quantification of multiple biomarker expression in circulating tumor cells
Hsieh, H., Bethel, K., Curry, D., Jeffrey, S., Krivacic, R., Kuhn, P., … Bruce, R. (2009). Y Quantification of multiple biomarker expression in circulating tumor cells. CANCER RESEARCH, 69.

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., … Brahmer, J. R. (2014). Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S36.

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., … Schiller, J. H. (2017). Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. LANCET ONCOLOGY, 18(12), 1610–23.

Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., … Schiller, J. (2015). Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505. JOURNAL OF THORACIC ONCOLOGY, 10(9), S796.

Risk Stratification for Second Primary Lung Cancer
Han, S. S., Rivera, G. A., Tammemagi, M. C., Plevritis, S. K., Gomez, S. L., Cheng, I., & Wakelee, H. A. (2017). Risk Stratification for Second Primary Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY, 35(25), 2893-+.

SERIAL MONITORING OF PLASMA EGFR T790M LEVELS AND EVALUATION OF EGFR MUTATIONAL STATUS IN MATCHED TISSUE AND PLASMA FROM NSCLC PATIENTS TREATED WITH CO-1686
Wakelee, H. A., Karlovich, C. A., Wen, W., Sun, J.-M., Chien, S., Mann, E., … Park, K. (2013). SERIAL MONITORING OF PLASMA EGFR T790M LEVELS AND EVALUATION OF EGFR MUTATIONAL STATUS IN MATCHED TISSUE AND PLASMA FROM NSCLC PATIENTS TREATED WITH CO-1686. JOURNAL OF THORACIC ONCOLOGY, 8, S388–S389.

Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686
Dziadziuszko, R., Karlovich, C., Wen, W., Sun, J.-M., Chien, S., Mann, E., … Park, K. (2014). Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686. CANCER RESEARCH, 74(19).

Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686.
Sun, J.-M., Karlovich, C., Wen, W., Wakelee, H., Chien, S., Mann, E., … Park, K. (2013). Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686. MOLECULAR CANCER THERAPEUTICS, 12(11).

Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., … Gensheimer, M. F. (2018). Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. Clinical Lung Cancer.

ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION
Das, M., Padda, S. K., Zhou, L., Frymoyer, A., Neal, J. W., & Wakelee, H. A. (2013). ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA)
Padda, S. K., Riess, J., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., … Wakelee, H. A. (2014). Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA). JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Rociletinib-associated cataracts in EGFR-mutant NSCLC
Piotrowska, Z., Liu, E., Varga, A., Thakur, M., Narayanan, V., Liu, S. V., … Sequist, L. V. (2016). Rociletinib-associated cataracts in EGFR-mutant NSCLC. ANNALS OF ONCOLOGY, 27.

ENERGY METABOLISM IN LUNG ADENOCARCINOMA
Hoang, C., Xu, Y., Shi, Z., Lin, Y., Merritt, R. E., Shrager, J., … Wakelee, H. A. (2013). ENERGY METABOLISM IN LUNG ADENOCARCINOMA. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer
Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C., Zhu, H., Eclov, N. C. W., To, J., … Loo, B. W. (2017). Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. RADIOTHERAPY AND ONCOLOGY, 125(2), 338–43.

PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES PREVIOUSLY TREATED WITH CHEMOTHERAPY
Liang, Y., Padda, S. K., Riess, J. W., West, R., Neal, J. W., & Wakelee, H. A. (2014). PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES PREVIOUSLY TREATED WITH CHEMOTHERAPY. JOURNAL OF THORACIC ONCOLOGY, 9(10), S226.

STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES
Wakelee, H., Riess, J., Pedro-Salcedo, M. S., Padda, S., Ramchandran, K., Gubens, M., & Neal, J. (2013). STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES. JOURNAL OF THORACIC ONCOLOGY, 8, 22–23.

CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts)
Reckamp, K. L., Wakelee, H. A., Patel, S., Blumenschein, G., Neal, J. W., Gitlitz, B., … Horn, L. (2017). CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts). ANNALS OF ONCOLOGY, 28.

PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EXPRESSION IN A THYMOMA TISSUE MICROARRAY (TMA)
Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., … Wakelee, H. A. (2014). PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EXPRESSION IN A THYMOMA TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 9(10), S212.

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial
Modlin, L. A., Choi, C. Y. H., Gibbs, I. C., Wakelee, H. A., Neal, J., Pinder-Schenck, M. C., … Soltys, S. G. (2015). Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Padda, S. K., Rosenberg-Hasson, Y., Neal, J. W., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., … Zhou, L. (2013). CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC). JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., … Kelly, R. J. (2018). Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. LUNG CANCER, 117, 44–49.

Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC
Horn, L., Wakelee, H., Reckamp, K., Blumenschein, G., Infante, J., Carter, C., … Lovly, C. (2017). Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC. JOURNAL OF THORACIC ONCOLOGY, 12(1), S1159.

PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA
Padda, S. K., Pagtama, J. Y., Tisch, A. H., Neal, J. W., Riess, J. W., Loo, B. W., … Wakelee, H. A. (2014). PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA. JOURNAL OF THORACIC ONCOLOGY, 9(10), S240–S241.

A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer
Nagpal, S., Wakelee, H., Padda, S., Bertrand, S., Acevedo, B., Tisch, A. H., … Neal, J. (2017). A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Computed Tomography (CT) Characteristics Associated with the Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma
Padda, S. K., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., … Wakelee, H. A. (2015). Computed Tomography (CT) Characteristics Associated with the Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma. JOURNAL OF THORACIC ONCOLOGY, 10(9), S196.

GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)
Riess, J. W., West, R., Padda, S. K., Dean, M., Klimowicz, A., Huong, C., … Wakelee, H. A. (2013). GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 8, S944.

Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies
Chuang, J., Neal, J. W., & Wakelee, H. A. (2015). Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies. JOURNAL OF THORACIC ONCOLOGY, 10(9), S549.

VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus /- Erlotinib in Non-Small Cell Lung Cancer
Padda, S. K., Lara, P., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., West, H., … Wakelee, H. A. (2015). VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus /- Erlotinib in Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.
Sequist, L. V., Soria, J.-C., Gadgeel, S. M., Wakelee, H. A., Camidge, D. R., Varga, A., … Goldman, J. W. (2013). First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. JOURNAL OF CLINICAL ONCOLOGY, 31(15).

A Phase lb Study of Erlotinib and Momelotinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer
Padda, S., Reckamp, K., Koczywas, M., Neal, J., Brachmann, C., Kawashima, J., … Wakelee, H. (2017). A Phase lb Study of Erlotinib and Momelotinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES
Wakelee, H. A., Riess, J. W., San Pedro-Salcedo, M., Padda, S. K., Ramchandran, K., Gubens, M. A., & Neal, J. W. (2013). STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES. JOURNAL OF THORACIC ONCOLOGY, 8, S731.

GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)
Riess, J., West, R., Padda, S., Dean, M., Klimowicz, A., Huong, C., … Wakelee, H. (2013). GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 8, 25.

Phase II Trial of Single Agent Amrubicin in Patients with Previously Treated Advanced Thymic Malignancies
Wakelee, H. A., Padda, S. K., Burns, M., Spittler, A. J., Riess, J. W., San Pedro-Salcedo, M., … Loehrer, P. J. (2015). Phase II Trial of Single Agent Amrubicin in Patients with Previously Treated Advanced Thymic Malignancies. JOURNAL OF THORACIC ONCOLOGY, 10(9), S195.

A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC)
Neal, J. W., Wakelee, H. A., Feliciano, J. L., Goldberg, S. B., Morgensztern, D., Das, M. S., … Sequist, L. V. (2014). A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 32(15).

COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSOCIATED WITH MASAOKA-KOGA PATHOLOGIC STAGE IN THYMOMA
Padda, S. K., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., … Wakelee, H. A. (2014). COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSOCIATED WITH MASAOKA-KOGA PATHOLOGIC STAGE IN THYMOMA. JOURNAL OF THORACIC ONCOLOGY, 9(10), S222.

FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)
Soria, J.-C., Sequist, L. V., Gadgeel, S., Goldman, J., Wakelee, H., Varga, A., … Allen, A. (2013). FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M). JOURNAL OF THORACIC ONCOLOGY, 8, S141–S142.

Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer
Xiang, M., Gensheimer, M. F., Maxim, P. G., Wakelee, H. A., Neal, J. W., Diehn, M., & Loo, B. W. (2017). Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), E504.

VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS
Nguyen, K.-S. H., Das, M., Ramchandran, K., Shrager, J., Merritt, R. E., Hoang, C., … Neal, J. W. (2013). VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.
Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H. A., … Alizadeh, A. A. (2014). Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma
Wakelee, H., Melnikova, V., Karlovich, C., Gadgeel, S., Reckamp, K., Goldman, J. W., … Sequist, L. (2017). A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma. JOURNAL OF THORACIC ONCOLOGY, 12(1), S384–S385.

Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 98(2), E4.

PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER
Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., … Blayney, D. (2013). PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER. JOURNAL OF THORACIC ONCOLOGY, 8, S1324.

Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors
Padda, S. K., Terrone, D., Tian, L., Khuong, A., Neal, J. W., Riess, J. W., … Wakelee, H. A. (2018). Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors. JOURNAL OF THORACIC IMAGING, 33(3), 176–83.

SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., … Sequist, L. V. (2014). SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D. P., & Ramalingam, S. S. (2015). Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512). JOURNAL OF CLINICAL ONCOLOGY, 33(15).

A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D. P., & Ramalingam, S. S. (2015). A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512. JOURNAL OF THORACIC ONCOLOGY, 10(9), S373.

Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).
Wakelee, H. A., Padda, S. K., Burns, M., Spittler, A. J., Riess, J., San Pedro-Salcedo, M., … Loehrer, P. J. (2015). Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM). JOURNAL OF CLINICAL ONCOLOGY, 33(15).

Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma
Gao, R. W., Berry, M. F., Kunder, C. A., Khuong, A. A., Wakelee, H., Neal, J. W., … Shrager, J. B. (2017). Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 154(6), 2092-+.

Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
Horn, L., Wakelee, H., Blumenschein, G., Reckamp, K., Waqar, S., Carter, C. A., … Lovly, C. (2016). Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx). ANNALS OF ONCOLOGY, 27.

Recreational activity and sedentary behavior in relation to lung cancer incidence and mortality in the Women's Health Initiative
Wang, A., Qin, F. F., Hedlin, H., Desai, M., Chlebowski, R. T., Gomez, S. L., … Stefanick, M. L. (2015). Recreational activity and sedentary behavior in relation to lung cancer incidence and mortality in the Women's Health Initiative. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS
Niu, X., Chuang, J. C., Berry, G. J., & Wakelee, H. A. (2017). Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 18(12), 71.

Perspectives on Acquired Resistance to PD-1 AxisInhibitors in Patients with Non-Small Cell LungCancer.
Tseng, D., Padda, S. K., & Wakelee, H. A. (2018). Perspectives on Acquired Resistance to PD-1 AxisInhibitors in Patients with Non-Small Cell LungCancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 13(6), 741–44.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Miller, J. S., Morishima, C., McNeel, D. G., Patel, M. R., Kohrt, H. E. K., Thompson, J. A., … Conlon, K. C. (2018). A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. CLINICAL CANCER RESEARCH, 24(7), 1525–35.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma
Krug, A. K., Enderle, D., Karlovich, C., Priewasser, T., Bentink, S., Spiel, A., … Skog, J. (2018). Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. ANNALS OF ONCOLOGY, 29(3), 700–706.

A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy
Gubens, M. A., Chuang, J. C., Akerley, W., Langer, C. J., Clement-Duchene, C., San Pedro-Salcedo, M., … Wakelee, H. A. (2018). A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. JOURNAL OF THORACIC DISEASE, 10(1), 219–27.

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database
Padda, S. K., Yao, X., Antonicelli, A., Riess, J. W., Shang, Y., Shrager, J. B., … Badve, S. S. (2018). Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. JOURNAL OF THORACIC ONCOLOGY, 13(3), 436–46.

Does Plasma-Based Molecular Testing Have a Role in the Routine Care of Lung Cancer?
Wakelee, H. (2017). Does Plasma-Based Molecular Testing Have a Role in the Routine Care of Lung Cancer? CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 15(8), 599–601.

Heather Wakelee on the role of checkpoint inhibitors in advanced lung cancer
Wakelee, H. (2017). Heather Wakelee on the role of checkpoint inhibitors in advanced lung cancer. ONCOLOGY-NEW YORK, 31(6), 440-+.

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Socinski, M. A., Obasaju, C., Gandara, D., Hirsch, F. R., Bonomi, P., Bunn, P. A., … Thatcher, N. (2018). Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 13(2), 165–83.

The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront?
Zweig, J., & Wakelee, H. (2017). The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront? AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 13(9), 32–36.

Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., … Diehn, M. (2018). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease
Varlotto, J. M., Voland, R., McKie, K., Flickinger, J. C., DeCamp, M. M., Maddox, D., … Walsh, W. (2018). Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. CANCER MEDICINE, 7(4), 1211–20.

Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017.
Donington, J. S., Kim, Y. T., Tong, B., Moreira, A. L., Bessich, J., Weiss, K. D., … Van Schil, P. (2018). Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 13(6), 767–78.

Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California
DeRouen, M. C., Hu, L., McKinley, M., Gali, K., Patel, M., Clarke, C., … Cheng, I. (2018). Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California. PLOS ONE, 13(5), e0197146.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Horn, L., Infante, J. R., Reckamp, K. L., Blumenschein, G. R., Leal, T. A., Waqar, S. N., … Wakelee, H. A. (2018). Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. CLINICAL CANCER RESEARCH, 24(12), 2771–79.

IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC
Wakelee, H., Altorki, N., Vallieres, E., Zhou, C., Zuo, Y., Howland, M., … Felip, E. (2017). IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC. JOURNAL OF THORACIC ONCOLOGY, 12(1), S1305.

50 Years of progress in the systemic therapy of non-small cell lung cancer.
Wakelee, H., Kelly, K., & Edelman, M. J. (2014). 50 Years of progress in the systemic therapy of non-small cell lung cancer. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting, 177–89.

Lung Cancer Survival Among Chinese Americans, 2000 to 2010.
Gomez, S. L., Yang, J., Lin, S.-W., McCusker, M., Sandler, A., Patel, M., … Clarke, C. A. (2016). Lung Cancer Survival Among Chinese Americans, 2000 to 2010. Journal of Global Oncology, 2(1), 30–38.

The J-ALEX trial-is frontline alectinib a new standard of care?
Zweig, J., & Wakelee, H. A. (2017). The J-ALEX trial-is frontline alectinib a new standard of care? JOURNAL OF THORACIC DISEASE, 9(8), 2242–45.

Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years
Patel, M. I., McKinley, M., Cheng, I., Haile, R., Wakelee, H., & Gomez, S. L. (2017). Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years. LUNG CANCER, 108, 140–49.

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)
Sequist, L. V., Soria, J.-C., Gadgeel, S. M., Wakelee, H. A., Camidge, D. R., Varga, A., … Goldman, J. W. (2014). First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). JOURNAL OF CLINICAL ONCOLOGY, 32(15).

FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)
Wakelee, H., Soria, J., Camidge, R., Gadgeel, S., Goldman, J., Varga, A., … Sequist, L. V. (2014). FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M). JOURNAL OF THORACIC ONCOLOGY, 9(4), S38.

INCREASED GALECTIN-1 EXPRESSION IN A THYMIC EPITHELIAL TUMOR TISSUE MICROARRAY (TMA)
Riess, J., Kuo, P., Kong, C., West, R., Padda, S., Wakelee, H., & Le, Q. (2013). INCREASED GALECTIN-1 EXPRESSION IN A THYMIC EPITHELIAL TUMOR TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 8, 25–26.

Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.
Sikic, B. I., Eckhardt, S. G., Gallant, G., Burris, H. A., Camidge, D. R., Colevas, A. D., … Infante, J. R. (2011). Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. JOURNAL OF CLINICAL ONCOLOGY, 29(15).

Vascular Endothelial Growth Factor Pathway
Krupitskaya, Y., & Wakelee, H. (2009). Vascular Endothelial Growth Factor Pathway. JOURNAL OF THORACIC ONCOLOGY, 4(11), S1071–S1073.

Statin use and all-cancer mortality: Prospective results from the Women's Health Initiative
Wang, A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. A. E., Chlebowski, R. T., … Stefanick, M. L. (2015). Statin use and all-cancer mortality: Prospective results from the Women's Health Initiative. JOURNAL OF CLINICAL ONCOLOGY, 33(15).

A Phase 1 Trial of X-396, a Novel ALK Inhibitor, in Patients With Advanced Solid Tumors
Horn, L., Blumenscheine, G., Wakelee, H. A., Arkenau, T. H., Dukart, G., Harrow, K., … Infante, J. R. (2014). A Phase 1 Trial of X-396, a Novel ALK Inhibitor, in Patients With Advanced Solid Tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S52–S53.

ARE THERE DISPARITIES IN LUNG CANCER INCIDENCE TRENDS AMONG HISPANICS AND AFRICAN AMERICANS? AN ANALYSIS OF THE SURVEILLANCE EPIDEMIOLOGY AND END RESULTS DATABASE 1992-2010
Patel, M. I., Cheng, I., Gomez, S. L., Gali, K., Haile, R., & Wakelee, H. A. (2013). ARE THERE DISPARITIES IN LUNG CANCER INCIDENCE TRENDS AMONG HISPANICS AND AFRICAN AMERICANS? AN ANALYSIS OF THE SURVEILLANCE EPIDEMIOLOGY AND END RESULTS DATABASE 1992-2010. JOURNAL OF THORACIC ONCOLOGY, 8, S1293.

A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).
Wakelee, H. A., Gettinger, S. N., Engelman, J. A., Janne, P. A., West, H. J., Subramaniam, D. S., … Lara, P. (2010). A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 28(15).

A POOLED ANALYSIS OF ADVANCED NONSQUAMOUS NSCLC PATIENTS WITH STABLE TREATED BRAIN METASTASES IN TWO PHASE II TRIALS RECEIVING BEVACIZUMAB AND PEMETREXED AS SECOND-LINE THERAPY
Gubens, M., Akerley, W., Lynch, T., Langer, C. J., Socinski, M. A., Colevas, A. D., … Wakelee, H. (2011). A POOLED ANALYSIS OF ADVANCED NONSQUAMOUS NSCLC PATIENTS WITH STABLE TREATED BRAIN METASTASES IN TWO PHASE II TRIALS RECEIVING BEVACIZUMAB AND PEMETREXED AS SECOND-LINE THERAPY. JOURNAL OF THORACIC ONCOLOGY, 6(6), S1224–S1225.

PRIMARY CHEMOTHERAPY FOR THYMIC MALIGNANCIES
Wakelee, H. (2012). PRIMARY CHEMOTHERAPY FOR THYMIC MALIGNANCIES. JOURNAL OF THORACIC ONCOLOGY, 7(11), S412.

An Update on Clinical Trials: Is Tumor Angiogenesis Still a Viable Target in Advanced NSCLC?
Wakelee, H. A. (2015). An Update on Clinical Trials: Is Tumor Angiogenesis Still a Viable Target in Advanced NSCLC? JOURNAL OF THORACIC ONCOLOGY, 10(9), S94–S95.

Description of ALK plus NSCLC Patient Characteristics and ALK Testing Patterns
Wakelee, H. A., Sasane, M., Zhang, J., Macalalad, A. R., Galebach, P., Jarvis, J., … Guerin, A. (2014). Description of ALK plus NSCLC Patient Characteristics and ALK Testing Patterns. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S60–S61.

TREATMENT AND SURVIVAL PATTERNS AMONG ALK plus NSCLC PATIENTS FOLLOWING CRIZOTINIB DISCONTINUATION
Guerin, A., Wakelee, H., Sasane, M., Zhang, J., Galebach, P., Jarvis, J., … Macalalad, A. R. (2014). TREATMENT AND SURVIVAL PATTERNS AMONG ALK plus NSCLC PATIENTS FOLLOWING CRIZOTINIB DISCONTINUATION. VALUE IN HEALTH, 17(3), A73.

INTERIM REPORT OF ON-STUDY DEMOGRAPHICS AND TOXICITY FROM EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) E1505, A PHASE III RANDOMIZED TRIAL OF ADJUVANT CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB FOR COMPLETELY RESECTED EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Gandara, D. R., Graziano, S., Leighl, N. B., … Schiller, J. (2011). INTERIM REPORT OF ON-STUDY DEMOGRAPHICS AND TOXICITY FROM EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) E1505, A PHASE III RANDOMIZED TRIAL OF ADJUVANT CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB FOR COMPLETELY RESECTED EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 6(6), S464.

TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.
Yang, J. C.-H., Popat, S., Georgiou, P., Miyamoto, E., Isaacson, J. D., & Wakelee, H. A. (2015). TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Anti-angiogenic Agents in Metastatic NSCLC
Das, M., & Wakelee, H. (2014). Anti-angiogenic Agents in Metastatic NSCLC. LUNG CANCER,4TH EDITION, 527–40.

Management of early stage non-small cell lung cancer
Wakelee, H. (2013). Management of early stage non-small cell lung cancer. TRANSLATIONAL LUNG CANCER RESEARCH, 2(5), 315.

Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC)
Liang, Y., & Wakelee, H. A. (2013). Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). TRANSLATIONAL LUNG CANCER RESEARCH, 2(5), 403–10.

Lung Cancer Incidence by Histology, Gender, Race/Ethnicity and Socioeconomic Status
Patel, M. I., Mckinley, M., Cheng, I., Wakelee, H. A., & Gomez, S. (2015). Lung Cancer Incidence by Histology, Gender, Race/Ethnicity and Socioeconomic Status. JOURNAL OF THORACIC ONCOLOGY, 10(9), S460–S461.

TIGER-3: A Phase 3 Open-Label, Randomized Study of Rociletinib vs Chemotherapy in NSCLC
Yang, J. C.-H., Popat, S., Bazhenova, L., Blakely, C. M., Dichman, R., Felip, E., … Wakelee, H. A. (2015). TIGER-3: A Phase 3 Open-Label, Randomized Study of Rociletinib vs Chemotherapy in NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

INCREASED GALECTIN-1 EXPRESSION IN A THYMIC EPITHELIAL TUMOR TISSUE MICROARRAY (TMA) AND GALECTIN-1 KNOCKDOWN STUDIES IN A THYMOMA CELL LINE
Riess, J. W., Kuo, P., Kong, C., Wakelee, H. A., West, R., & Quynh Le. (2013). INCREASED GALECTIN-1 EXPRESSION IN A THYMIC EPITHELIAL TUMOR TISSUE MICROARRAY (TMA) AND GALECTIN-1 KNOCKDOWN STUDIES IN A THYMOMA CELL LINE. JOURNAL OF THORACIC ONCOLOGY, 8, S269.

Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Gandara, D. R., Graziano, S. L., Leighl, N. B., … Schiller, J. H. (2011). Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 29(15).

A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors.
Townsley, C. A., Siu, L. L., Pedro-Salcedo, M. S., Liu, L., & Wakelee, H. A. (2010). A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 28(15).

Survival after non-small cell lung cancer in never-smoking Asian/Pacific Islander and Latina women
Wakelee, H. A., Chang, E. T., Shema, S., Reynolds, P., Clement-Duchene, C., Wiencke, J., & Gomez, S. L. (2009). Survival after non-small cell lung cancer in never-smoking Asian/Pacific Islander and Latina women. JOURNAL OF THORACIC ONCOLOGY, 4(9), S310.

LUNG CANCER INCIDENCE TRENDS AMONG ASIAN-AMERICAN ETHNIC POPULATIONS IN THE UNITED STATES, 1990-2010
Gomez, S. L., Cheng, I., Gali, K., Patel, M. I., Haile, R., Noone, A.-M., & Wakelee, H. (2013). LUNG CANCER INCIDENCE TRENDS AMONG ASIAN-AMERICAN ETHNIC POPULATIONS IN THE UNITED STATES, 1990-2010. JOURNAL OF THORACIC ONCOLOGY, 8, S233.

Commentary: Highlights in NSCLC From the 15th World Conference on Lung Cancer
Wakelee, H. A. (2014). Commentary: Highlights in NSCLC From the 15th World Conference on Lung Cancer. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 12(1), 17–21.

Adjuvant Chemotherapyfor Early-Stage Non-Small Cell Lung Cancer
Patel, M. I., & Wakelee, H. A. (2012). Adjuvant Chemotherapyfor Early-Stage Non-Small Cell Lung Cancer. LUNG CANCER, 3(1), 129–40.

IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC
Zhou, C., Altorki, N., Vallieres, E., Felip, E., Zuo, Y., Howland, M., … Wakelee, H. (2016). IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC. ANNALS OF ONCOLOGY, 27.

Association of non-melanoma skin cancer with second non-cutaneous malignancy in the Women's Health Initiative
Ransohoff, K., Stefanick, M., Li, S., Kurian, A., Wakelee, H., Wang, A., … Tang, J. (2016). Association of non-melanoma skin cancer with second non-cutaneous malignancy in the Women's Health Initiative. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 136(5), S36.

Symptoms and QOL with Ceritinib in ALK plus NSCLC Patients with/without Brain Metastases
Crino, L., Ahn, M.-J., De Marinis, F., Groen, H. J. M., Wakelee, H. A., Hida, T., … Spigel, D. (2015). Symptoms and QOL with Ceritinib in ALK plus NSCLC Patients with/without Brain Metastases. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

MID-RADIATION THERAPY PET CORRELATES WITH SURVIVAL IN LOCALLY ADVANCED NSCLC
Loo, B. W., Chang, C., Hong, J., Wakelee, H., Quynh Thu Le, Hara, W. Y., … Olson, M. (2011). MID-RADIATION THERAPY PET CORRELATES WITH SURVIVAL IN LOCALLY ADVANCED NSCLC. JOURNAL OF THORACIC ONCOLOGY, 6(6), S694–S695.

Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer
Soria, J., Sequist, L. V., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., … Camidge, R. D. (2014). Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer. EUROPEAN JOURNAL OF CANCER, 50, 199.

ARE PATIENTS' NEEDS BEING MET AFTER-HOURS? AN EVALUATION OF PHONE CALLS MADE AFTER HOURS FOR PATIENTS WITH THORACIC MALIGNANCIES.
Patel, M. I., Williams, D., Wohlforth, C., Fisher, G. A., Blayney, D., & Wakelee, H. A. (2013). ARE PATIENTS' NEEDS BEING MET AFTER-HOURS? AN EVALUATION OF PHONE CALLS MADE AFTER HOURS FOR PATIENTS WITH THORACIC MALIGNANCIES. JOURNAL OF THORACIC ONCOLOGY, 8, S709.

Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK plus NSCLC
Leal, T., Wakelee, H., Infante, J., Blumenschein, G., Reckamp, K., Carter, C., … Horn, L. (2016). Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK plus NSCLC. JOURNAL OF THORACIC ONCOLOGY, 11(10), S176–S177.

Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial
Soria, J. C., Goldman, J. W., Wakelee, H., Gadgeel, S., Camidge, D. R., Solomon, B., … Sequist, L. V. (2015). Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial. EUROPEAN JOURNAL OF CANCER, 51, S637.

A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM)
Wakelee, H. A., Fehling, J. M., Molina, J. R., Lensing, J. L., Funke, R. P., Miles, D., & Sikic, B. I. (2008). A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM). JOURNAL OF CLINICAL ONCOLOGY, 26(15).

Angiogenesis in lung cancer: role of anti-angiogenic TKI's
Wakelee, H. A., & Clement-Duchene, C. (2009). Angiogenesis in lung cancer: role of anti-angiogenic TKI's. JOURNAL OF THORACIC ONCOLOGY, 4(9), S24–S26.

Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)
Wakelee, H. A., Zvirbule, Z., De Braud, F., Kingsley, C. D., Mekhail, T., Schuette, W., … Novello, S. (2014). Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S37–S38.

A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ONARTUZUMAB (METMAB) WITH EITHER BEVACIZUMAB plus PLATINUM plus PACLITAXEL OR PEMETREXED plus PLATINUM AS FIRST-LINE TREATMENT FOR PATIENTS (PTS) WITH STAGE IIIB OR IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Wakelee, H., Yu, W., Rittweger, K., & Paton, V. E. (2012). A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ONARTUZUMAB (METMAB) WITH EITHER BEVACIZUMAB plus PLATINUM plus PACLITAXEL OR PEMETREXED plus PLATINUM AS FIRST-LINE TREATMENT FOR PATIENTS (PTS) WITH STAGE IIIB OR IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC). ANNALS OF ONCOLOGY, 23, 445.

Perspectives of Targeted Therapies and Immunotherapy in Completely Resected NSCLC
Wakelee, H. (2017). Perspectives of Targeted Therapies and Immunotherapy in Completely Resected NSCLC. JOURNAL OF THORACIC ONCOLOGY, 12(1), S45–S46.

Ceritinib in ALK plus NSCLC Metastatic to Brain and/or Leptomeninges: The ASCEND-7 Study
Chow, L. Q., Barlesi, F., Bertino, E. M., Kim, D.-W., Van Den Bent, M. J., Wakelee, H. A., … Branle, F. (2015). Ceritinib in ALK plus NSCLC Metastatic to Brain and/or Leptomeninges: The ASCEND-7 Study. JOURNAL OF THORACIC ONCOLOGY, 10(9), S550–S551.

Smoking and estrogen plus progestin (E plus P) and lung cancer incidence and mortality.
Chlebowski, R. T., Wakelee, H. A., Rohan, T. E., Liu, J., Simon, M. S., Tindle, H., … Gass, M. (2013). Smoking and estrogen plus progestin (E plus P) and lung cancer incidence and mortality. JOURNAL OF CLINICAL ONCOLOGY, 31(15).

Pretreatment and serial plasma assessments of EGFR mutations in NSCLC patients treated with rociletinib (CO-1686)
Goldman, J. W., Karlovich, C., Mann, E., Rolfe, L., Matheny, S., Despain, D., … Sequist, L. V. (2015). Pretreatment and serial plasma assessments of EGFR mutations in NSCLC patients treated with rociletinib (CO-1686). CANCER RESEARCH, 75.

Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test
Gadgeel, S., Soria, J. C., Goldman, J. W., Wakelee, H., Camidge, D. R., Yu, H., … Sequist, L. V. (2015). Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test. EUROPEAN JOURNAL OF CANCER, 51, S628.

A population-based study of incidence and survival trends of 1,261 thymic malignancies (TM): Results from the California Cancer Registry (CCR).
Riess, J., Chen, Y., Lara, P., Wakelee, H. A., Gubens, M. A., & Cress, R. D. (2014). A population-based study of incidence and survival trends of 1,261 thymic malignancies (TM): Results from the California Cancer Registry (CCR). JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.
Eckhardt, S. G., Gallant, G., Sikic, B. I., Camidge, D. R., Burris, H. A., Wakelee, H. A., … Infante, J. R. (2010). Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 28(15).

A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer
Harris, J. P., Patel, M. I., Loo, B. W., Wakelee, H. A., & Diehn, M. (2017). A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. LUNG CANCER, 108, 173–82.

Description of ALK plus NSCLC patient characteristics and ALK testing patterns
Wakelee, H. A., Sasane, M., Zhang, J., Macalalad, A. R., Galebach, P. J., Jarvis, J., … Guerin, A. (2014). Description of ALK plus NSCLC patient characteristics and ALK testing patterns. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).
Mok, T., Spigel, D., Felip, E., deMarinis, F., Ahn, M.-J., Groen, H. J. M., … Shaw, A. T. (2015). ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Smoking Behavior in Patients with Early Stage Non-Small Cell Lung Cancer: A Report from ECOG-ACRIN 1505 Trial
Ramalingam, S., Dahlberg, S., Wakelee, H., Keller, S., Tester, W., Gandara, D. R., … Schiller, J. (2017). Smoking Behavior in Patients with Early Stage Non-Small Cell Lung Cancer: A Report from ECOG-ACRIN 1505 Trial. JOURNAL OF THORACIC ONCOLOGY, 12(1), S256.

Stage IIIB and IV NSCLC: Primary Therapy
Das, M., & Wakelee, H. (2011). Stage IIIB and IV NSCLC: Primary Therapy. LUNG CANCER: A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND MANAGEMENT, 183–95.

Keynote Address: When Breath Becomes Air-As Physician Becomes Patient
Kalanithi, L., Wakelee, H., & Carlson, R. W. (2017). Keynote Address: When Breath Becomes Air-As Physician Becomes Patient. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(5.5), 696–98.

Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).
Sequist, L. V., Goldman, J. W., Wakelee, H. A., Camidge, D. R., Yu, H. A., Varga, A., … Soria, J.-C. (2015). Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial
Miller, V. A., Wakelee, H. A., Lara, P. N., Cho, J., Chowhan, N. M., Costa, D., … Lynch, T. J. (2008). Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial. JOURNAL OF CLINICAL ONCOLOGY, 26(15).

Activity of Rociletinib in EGFR Mutant NSCLC Patients with a History of CNS Involvement
Camidge, D. R., Sequist, L. V., Soria, J.-C., Wakelee, H. A., Ou, S.-H., Goldman, J. W., … Yu, H. (2015). Activity of Rociletinib in EGFR Mutant NSCLC Patients with a History of CNS Involvement. JOURNAL OF THORACIC ONCOLOGY, 10(9), S319.

Survival among never and ever smokers with lung cancer in the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study
Clement-Duchene, C., Xu, X., Gomez, S. L., Chang, E. T., West, D. W., Wakelee, H. A., & Gould, M. K. (2010). Survival among never and ever smokers with lung cancer in the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study. JOURNAL OF CLINICAL ONCOLOGY, 28(15).

BIOMARKERS FOR ANTI-ANGIOGENIC THERAPY
Das, M., & Wakelee, H. (2012). BIOMARKERS FOR ANTI-ANGIOGENIC THERAPY. JOURNAL OF THORACIC ONCOLOGY, 7(11), S442–S443.

Dose Optimization of Rociletinib for EGFR Mutated NSCLC
Goldman, J. W., Wakelee, H. A., Gadgeel, S., Camidge, D. R., Solomon, B. J., Yu, H., … Sequist, L. V. (2015). Dose Optimization of Rociletinib for EGFR Mutated NSCLC. JOURNAL OF THORACIC ONCOLOGY, 10(9), S318–S319.

Thymic malignancies (TM) in the United States: A population-based study of incidence and survival trends
Gubens, M. A., Clement-Duchene, C., & Wakelee, H. A. (2010). Thymic malignancies (TM) in the United States: A population-based study of incidence and survival trends. JOURNAL OF CLINICAL ONCOLOGY, 28(15).

Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK plus NSCLC
Leal, T., Wakelee, H., Infante, J., Blumenschein, G., Reckamp, K., Carter, C., … Horn, L. (2016). Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK plus NSCLC. JOURNAL OF THORACIC ONCOLOGY, 11(10), S209–S210.

Efficacy of Rociletinib (CO-1686) in Centrally Confirmed T790M-positive and T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients (Pts)
Sequist, L. V., Goldman, J. W., Wakelee, H., Camidge, D. R., Gadgeel, S., Yu, H. A., … Soria, J.-C. (2016). Efficacy of Rociletinib (CO-1686) in Centrally Confirmed T790M-positive and T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients (Pts). ONCOLOGY RESEARCH AND TREATMENT, 39, 121.

Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement
Varga, A., Camidge, D. R., Sequist, L. V., Wakelee, H., Ou, S. H., Goldman, J. W., … Soria, J. C. (2015). Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. EUROPEAN JOURNAL OF CANCER, 51, S598.

Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative
Tao, M.-H., Dai, Q., Chen, S., Freudenheim, J. L., Rohan, T., Wakelee, H., … Wactawski-Wende, J. (2017). Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative. LUNG CANCER, 110, 42–47.

METLung: a disappointing result in a challenging patient population
Zweig, J., & Wakelee, H. (2017). METLung: a disappointing result in a challenging patient population. TRANSLATIONAL CANCER RESEARCH, 6, S489–S493.

Anti-angiogenesis drugs in lung cancer
Lee, S. M., Baas, P., & Wakelee, H. (2010). Anti-angiogenesis drugs in lung cancer. RESPIROLOGY, 15(3), 387–92.

Rociletinib in NSCLC Patients with Negative Central Testing for T790M in TIGER-X
Wakelee, H. A., Sequist, L. V., Gadgeel, S., Soria, J.-C., Goldman, J. W., Yu, H., … Papadimitrakopoulou, V. (2015). Rociletinib in NSCLC Patients with Negative Central Testing for T790M in TIGER-X. JOURNAL OF THORACIC ONCOLOGY, 10(9), S271–S272.

Are patients' needs being met after hours? An evaluation of phone calls made after hours for patients with thoracic malignancies.
Patel, M. I., Moore, D., Milstein, A., Wakelee, H. A., & Blayney, D. W. (2013). Are patients' needs being met after hours? An evaluation of phone calls made after hours for patients with thoracic malignancies. JOURNAL OF CLINICAL ONCOLOGY, 31(31).

Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M
Solomon, B., Wakelee, H., Sequist, L. V., Gadgeel, S., Soria, J. C., Goldman, J. W., … Besse, B. (2015). Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M. EUROPEAN JOURNAL OF CANCER, 51, S636.

A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.
Horn, L., Infante, J. R., Blumenschein, G. R., Wakelee, H. A., Arkenau, H.-T., Dukart, G., … Pao, W. (2014). A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib
Gadgeel, S., Chen, W., Piotrowska, Z., Goldman, J. W., Wakelee, H., Camidge, D. R., … Sequist, L. (2017). Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib. JOURNAL OF THORACIC ONCOLOGY, 12(1), S1263.

Are needs of stakeholders in cancer care being met? A novel approch to assessing needs to improve value in cancer care
Patel, M. I., Moore, D., Randolph, S., Wakelee, H. A., Blayney, D. W., & Milstein, A. (2013). Are needs of stakeholders in cancer care being met? A novel approch to assessing needs to improve value in cancer care. JOURNAL OF CLINICAL ONCOLOGY, 31(15).

Racial/ethnic variations in lung cancer incidence and mortality, adjusted for smoking behavior: Results from the Women's Health Initiative.
Patel, M. I., Wang, A., Kapphahn, K., Kubo, J., Desai, M., Chlebowski, R. T., … Wakelee, H. A. (2014). Racial/ethnic variations in lung cancer incidence and mortality, adjusted for smoking behavior: Results from the Women's Health Initiative. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Lung Cancer Sex Differences
Hsu, J. Y., & Wakelee, H. A. (2010). Lung Cancer Sex Differences. FEMALE SEX HORMONES AND CANCERS, 149–70.

Using Fiber Array Scanning Technology (FAST) Platform for sensitive detection and analysis of circulating tumor cells with a hybrid epithelial/mesenchymal phenotype from non-small cell lung cancer.
Liu, X., Ly, J. C., Kara, L., Wakelee, H., Collins, N., Laderoute, K., & Sambucetti, L. C. (2013). Using Fiber Array Scanning Technology (FAST) Platform for sensitive detection and analysis of circulating tumor cells with a hybrid epithelial/mesenchymal phenotype from non-small cell lung cancer. MOLECULAR CANCER THERAPEUTICS, 12(11).

A randomized discontinuation phase II study of sorafenib vs placebo in patients with non-small cell lung cancer (NSCLC) who failed at least two prior chemotherapy regimens: E2501
Schiller, J., Lee, J.-whei, Hanna, N. H., Traynor, A. M., Wakelee, H., & Carbone, D. P. (2009). A randomized discontinuation phase II study of sorafenib vs placebo in patients with non-small cell lung cancer (NSCLC) who failed at least two prior chemotherapy regimens: E2501. JOURNAL OF THORACIC ONCOLOGY, 4(9), S355–S356.

A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies
Wakelee, H. A., Padda, S. K., Chhatwani, L., Pedro-Salcedo, M. S., Krupitskaya, Y., Musib, L., & Latz, J. E. (2008). A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies. EJC SUPPLEMENTS, 6(12), 126.

Lung cancer and hormone replacement therapy reply
Chlebowski, R. T., Schwartz, A. G., Wakelee, H., & Anderson, G. L. (2010). Lung cancer and hormone replacement therapy reply. LANCET, 375(9709), 118–19.

Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)
Reckamp, K. L., Infante, J. R., Blumenschein, G. R., Wakelee, H., Carter, C. A., Gockerman, J. P., … Horn, L. (2016). Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 11(2), S36–S37.

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Hirsch, F. R., Kerr, K. M., Bunn, P. A., Kim, E. S., Obasaju, C., Perol, M., … Thatcher, N. (2018). Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. CLINICAL LUNG CANCER, 19(4), 331–39.

Development of a multilevel integrated dataset to study lung cancer incidence and risk factors in never-smoking Asian American, Native Hawaiian, and Pacific Islander females.
DeRouen, M. C., Shariff-Marco, S., Lichtensztajn, D., Jin, A., Daide, Y., Canchola, A. J., … Gomez, S. L. (2018). Development of a multilevel integrated dataset to study lung cancer incidence and risk factors in never-smoking Asian American, Native Hawaiian, and Pacific Islander females. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 27(7), 81–82.

A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.
Das, M., Padda, S. K., Frymoyer, A., Molina, J., Adjei, A., Lensing, J. L., … Wakelee, H. A. (2018). A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology.

Oral bisphosphonate use and lung cancer incidence among postmenopausal women
Tao, M. H., Chen, S., Freudenheim, J. L., Cauley, J. A., Johnson, K. C., Mai, X., … Wactawski-Wende, J. (2018). Oral bisphosphonate use and lung cancer incidence among postmenopausal women. ANNALS OF ONCOLOGY, 29(6), 1476–85.

Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2018). Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. The Oncologist.

Caution Needed for Analyzing the Risks of Second Cancers.
Han, S. S., Plevritis, S. K., & Wakelee, H. A. (2018). Caution Needed for Analyzing the Risks of Second Cancers. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 13(9), e172–e173.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
Bonomi, P. D., Gandara, D., Hirsch, F. R., Kerr, K. M., Obasaju, C., Paz-Ares, L., … Thatcher, N. (2018). Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. ANNALS OF ONCOLOGY, 29(8), 1701–9.

Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.
Sun, T. Y., Niu, X., Chakraborty, A., Neal, J. W., & Wakelee, H. A. (2018). Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data
Leal, T., Wakelee, H., Reckamp, K., Waqar, S., Patel, S., Blumenschein, G., … Horn, L. (2018). Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data. JOURNAL OF THORACIC ONCOLOGY, 13(9), S156.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Rolfo, C., Mack, P. C., Scagliotti, G. V., Baas, P., Barlesi, F., Bivona, T. G., … Gandara, D. R. (2018). Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. JOURNAL OF THORACIC ONCOLOGY, 13(9), 1248–68.

Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.
Nguyen, K.-S. H., Stehr, H., Zhou, L., Nguyen, A.-H., Hiep, P. N., Van Cau, N., … Neal, J. W. (2018). Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. Journal of Global Oncology, (4), 1–9.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., … Sequist, L. V. (2018). SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1800131.

Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., & Wakelee, H. A. (2018). Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. Clinical Lung Cancer.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux, N., Gettinger, S. N., O'Kane, G., Arbour, K. C., Neal, J. W., Husain, H., … Sequist, L. V. (2018). EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801585.

How I Treat Advanced Stage Thymic Malignancy Patients
Wakelee, H. (2018). How I Treat Advanced Stage Thymic Malignancy Patients. JOURNAL OF THORACIC ONCOLOGY, 13(10), S222–S223.

eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients
Horn, L., Wu, Y., Reck, M., Wakelee, H., Liang, C., Harrow, K., … Mok, T. (2018). eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients. JOURNAL OF THORACIC ONCOLOGY, 13(10), S582.

Metabolomic Profiling for Second Primary Lung Cancer Among Lung Cancer Survivors
Han, S., Su, L., Diao, N., Christiani, D., & Wakelee, H. (2018). Metabolomic Profiling for Second Primary Lung Cancer Among Lung Cancer Survivors. JOURNAL OF THORACIC ONCOLOGY, 13(10), S567.

Effect of Induction Chemotherapy in the PACIFIC Study
Spigel, D., Vansteenkiste, J., Reck, M., Wakelee, H., Ozguroglu, M., Daniel, D., … Antonia, S. (2018). Effect of Induction Chemotherapy in the PACIFIC Study. JOURNAL OF THORACIC ONCOLOGY, 13(10), S629.

Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry
Gautschi, O., Drilon, A., Milia, J., Lusque, A., Mhanna, L., Li, B., … Mazieres, J. (2018). Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry. JOURNAL OF THORACIC ONCOLOGY, 13(10), S367.

Ensartinib Treatment Beyond Disease Progression in Stage IV ALK plus Non-Small Cell Lung Cancer
Horn, L., Pate, S., Waqar, S., Blumenschein, G., Harrow, K., Holzhausen, A., … Wakelee, H. (2018). Ensartinib Treatment Beyond Disease Progression in Stage IV ALK plus Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 13(10), S583.

Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool
Gandara, D., Quill, T., Edelman, M., Ramalingam, S., Wakelee, H., Fea, H., & Obholz, K. (2018). Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool. JOURNAL OF THORACIC ONCOLOGY, 13(10), S421.

Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center
Myall, N., Henry, S., Wood, D., Neal, J., & Wakelee, H. (2018). Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center. JOURNAL OF THORACIC ONCOLOGY, 13(10), S489–S490.

Computational Biological Model Prediction of PD-L1 Expression and Immunotherapy Response for KRAS Mutated Lung Cancer Based on Co-Mutations
Padda, S., Aredo, J., Vali, S., Singh, N., Vasista, S., Mitra, U., … Wakelee, H. (2018). Computational Biological Model Prediction of PD-L1 Expression and Immunotherapy Response for KRAS Mutated Lung Cancer Based on Co-Mutations. JOURNAL OF THORACIC ONCOLOGY, 13(10), S533.

Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model
Padda, S., Gokmen-Polar, Y., Badve, S., Vasista, S., Basu, K., Kumar, A., … Wakelee, H. (2018). Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model. JOURNAL OF THORACIC ONCOLOGY, 13(10), S606.

Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival
Moghavem, N., Wakelee, H. A., & Nagpal, S. (2018). Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival. ANNALS OF TRANSLATIONAL MEDICINE, 6.

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
Horn, L., Bauml, J., Forde, P. M., Davis, K. L., Myall, N. J., Sasane, M., … Johnson, B. E. (2019). Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 128, 74–90.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma
Krug, A. K., Enderle, D., Karlovich, C., Priewasser, T., Bentink, S., Spiel, A., … Skog, J. (2018). Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. ANNALS OF ONCOLOGY, 29(10), 2143.

Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang, S. X., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M. G., Diehn, M., … Neal, J. W. (2019). Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. Anti-Cancer Drugs.

Increased Galectin-1 Expression in Thymic Epithelial Tumors.
Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., & Le, Q.-T. (2018). Increased Galectin-1 Expression in Thymic Epithelial Tumors. Clinical Lung Cancer.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2019). First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1802018.

Prediction of PD-1 immunotherapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model
Wakelee, H., Aredo, J., Vali, S., Singh, N. K., Vasista, S. V., Mitra, U., … Padda, S. K. (2018). Prediction of PD-1 immunotherapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model. ANNALS OF ONCOLOGY, 29.

eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients
Horn, L., Wu, Y.-L., Reck, M., Wakelee, H., Liang, C., Harrow, K., … Mok, T. (2018). eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients. ANNALS OF ONCOLOGY, 29.

Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC)
Wakelee, H., Reckamp, K. L., Leal, T. A., Patel, S. P., Blumenschein, G., Shum, E., … Horn, L. (2018). Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC). ANNALS OF ONCOLOGY, 29.

SNS-595 demonstrates clinical activity and dose-proportional pharmacokinetics (PK) in two phase I clinical studies.
Hurwitz, H., Gordon, M., Advani, R., Ebbinghaus, S., Mendelson, D., Wakelee, H., … Adelman, D. (2006). SNS-595 demonstrates clinical activity and dose-proportional pharmacokinetics (PK) in two phase I clinical studies. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 136S.

Phase I trial of SNS-595 in patients (pts) with advanced malignancies.
Advani, R., Gordon, M., Hurwitz, H., Mendelson, D., Wakelee, H., Ebbinghaus, S., … Adelman, D. (2005). Phase I trial of SNS-595 in patients (pts) with advanced malignancies. CLINICAL CANCER RESEARCH, 11(24), 9056S.

Phase I trial of SNS-595 in patients with advanced malignancies.
Advani, R., Gordon, M., Hurwitz, H., Mendelson, D., Wakelee, H., Ebbinghaus, S., … Adelman, D. (2005). Phase I trial of SNS-595 in patients with advanced malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 159S.

A phase 1 trial of weekly SNS-595 in patients (PTS) with refractory cancer
Ebbinghaus, S., Gordon, M., Advani, R., Hurwitz, H., Mendelson, D., Wakelee, H., … Adelman, D. (2006). A phase 1 trial of weekly SNS-595 in patients (PTS) with refractory cancer. CANCER RESEARCH, 66(8).

A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients with advanced solid malignancies (ASM)
Molina, J., Wakelee, H. A., Fehling, J. M., Lensingi, J. L., Calcagni, J., Funke, R. F., … Sikic, B. I. (2007). A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients with advanced solid malignancies (ASM). MOLECULAR CANCER THERAPEUTICS, 6(12), 3508S–3509S.

A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI.
Sikic, B. I., Wakelee, H. A., Von Mehren, M., Lewis, N. L., Plummer, E. R., Calvert, A. H., … Burris, H. A. (2007). A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. MOLECULAR CANCER THERAPEUTICS, 6(12), 3454S–3455S.

A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI
Sikic, B. I., Wakelee, H. A., von Mehren, M., Lewis, N., Calvert, A. H., Plummer, E. R., … Burris, H. A. (2007). A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. JOURNAL OF CLINICAL ONCOLOGY, 25(18).

Quantification of progression of non-small cell lung cancer in the interval between diagnostic and radiotherapy treatment planning PET scans
Eastham, D. V., Weerasuriya, D., Wakelee, H., Quon, A., Maxim, P., Le, Q., … Loo, B. W. (2007). Quantification of progression of non-small cell lung cancer in the interval between diagnostic and radiotherapy treatment planning PET scans. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S520–S521.

Mid-treatment FDG-PET predicts disease progression in patients with non-small cell lung cancer
Olson, M. R., Weerasuriya, D. K., Wakelee, H. A., Quon, A., Maxim, P. G., Le, Q., … Loo, B. W. (2007). Mid-treatment FDG-PET predicts disease progression in patients with non-small cell lung cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S504.

Front line therapy with gemcitabine(G) administered immediately prior to pemetrexed (P) for patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical
West, H. J., Belt, R. J., Wakelee, H. A., Monberg, M. J., Frye, L. A., Ye, Z., & Obasaju, C. K. (2006). Front line therapy with gemcitabine(G) administered immediately prior to pemetrexed (P) for patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 393S.

HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors.
Patnaik, A., Wakelee, H., Mita, M., Fitzgerald, A., Hill, M., Fox, N., … Sikic, B. (2006). HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 123S.

HGS-ETR2-ST02: A phase 1 clinical trial of HGS-ETR2, a fully-human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors.
Sarantopoulos, J., Wakelee, H., Mita, M., Fitzgerald, A., Hill, M., Fox, N. L., … Sikic, B. (2005). HGS-ETR2-ST02: A phase 1 clinical trial of HGS-ETR2, a fully-human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors. CLINICAL CANCER RESEARCH, 11(24), 9104S.

Survival differences by gender for patients with advanced non-small cell lung cancer in Eastern Cooperative Oncology Group trial 1594
Wakelee, H., Wang, W., Schiller, J., Langer, C., Sandler, A., Belani, C., & Johnson, D. (2005). Survival differences by gender for patients with advanced non-small cell lung cancer in Eastern Cooperative Oncology Group trial 1594. LUNG CANCER, 49, S22.

Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer.
Wakelee, H. A. (2014). Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer. Clinical Advances in Hematology & Oncology : H&O, 12 Suppl 3(1), 17–21.

Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms
Davidzon, G., Wakelee, H., Neal, J., Mittra, E., Quon, A., & Iagaru, A. (2012). Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms. JOURNAL OF NUCLEAR MEDICINE, 53.

A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.
Wakelee, H. A., Altorki, N. K., Vallieres, E., Zhou, C., Zuo, Y., Howland, M., … Felip, E. (2017). A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010. JOURNAL OF CLINICAL ONCOLOGY, 35.

Risk factors associated with brain metastases in ECOG-ACRIN E1505, a phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>/=4 cm) - IIIA non-small cell lung cancer (NSCLC).
Varlotto, J. M., Dahlberg, S. E., Wakelee, H. A., Ramalingam, S. S., & Schiller, J. H. (2017). Risk factors associated with brain metastases in ECOG-ACRIN E1505, a phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>/=4 cm) - IIIA non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 35.

Tumor heterogeneity and testing discrepancy confound ROS1 detection in NSCLC.
Sun, T. Y., Stehr, H., Suarez, C. J., & Wakelee, H. A. (2019). Tumor heterogeneity and testing discrepancy confound ROS1 detection in NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors
Hellyer, J., Padda, S., & Wakelee, H. A. (2019). Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 104(1), 239.

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015). Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. Lung Cancer (Amsterdam, Netherlands), 89(3), 280–6.

Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival.
Moghavem, N., Wakelee, H. A., & Nagpal, S. (2018). Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival. Annals of Translational Medicine, 6(Suppl 2), S118.

Monitoring Neutropenia for Cancer Patients at the Point of Care.
Inan, H., Kingsley, J. L., Ozen, M. O., Tekin, H. C., Hoerner, C. R., Imae, Y., … Demirci, U. (2017). Monitoring Neutropenia for Cancer Patients at the Point of Care. Small Methods, 1(9).

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.
Paz-Ares, L., Hirsh, V., Zhang, L., de Marinis, F., Yang, J. C.-H., Wakelee, H. A., … Mok, T. S. (2015). Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 10(12), 1745–53.

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang, Y., Wakelee, H. A., & Neal, J. W. (2015). Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. Clinical Lung Cancer, 16(5), 366–73.

Lung cancer incidence trends by histology type among Asian American, Native Hawaiian, and Pacific Islander populations in the United States, 1990-2010.
Cheng, I., Le, G. M., Noone, A.-M. M., Gali, K., Patel, M., Haile, R. W., … Gomez, S. L. (2014). Lung cancer incidence trends by histology type among Asian American, Native Hawaiian, and Pacific Islander populations in the United States, 1990-2010. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 23(11), 2250–65.

Liquid Biopsy
Wakelee, H. (2017). Liquid Biopsy. JOURNAL OF THORACIC ONCOLOGY, 12(11), S1666–S1667.

First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study
Wu, Y., Mok, T., Reck, M., Wakelee, H., Liang, C., Tan, F., … Horn, L. (2017). First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study. JOURNAL OF THORACIC ONCOLOGY, 12(11), S2402.

Characterization of Autoantibody Responses in Thymoma with Myasthenia Gravis by Single-Cell Sequencing of B-cells
Gomez, A., Adamska, J., Padda, S., Preiss, J., Lingampalli, N., Wakelee, H., & Robinson, W. (2017). Characterization of Autoantibody Responses in Thymoma with Myasthenia Gravis by Single-Cell Sequencing of B-cells. JOURNAL OF THORACIC ONCOLOGY, 12(11), S1866–S1867.

Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA
Chabon, J., Chaudhuri, A., Azad, T., Kurtz, D., Stehr, H., Liu, C. L., … Diehn, M. (2017). Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)
Yang, J. C., Reckamp, K., Kim, Y., Novello, S., Smit, E., Lee, J., … Wakelee, H. (2017). Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 12(11), S2397.

IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC
Felip, E., Wakelee, H., Vallieres, E., Zhou, C., Zuo, Y., Xia, F., … Altorki, N. (2017). IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC. JOURNAL OF THORACIC ONCOLOGY, 12(11), S2398–S2399.

A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung
Padda, S., Reckamp, K., Koczywas, M., Neal, J., Kawashima, J., Kong, S., … Wakelee, H. (2017). A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung. JOURNAL OF THORACIC ONCOLOGY, 12(11), S2142–S2143.

Oral Bisphosphonate Use and Lung Cancer Incidence among Postmenopausal Women
Tao, M., Chen, S., Freudenheim, J. L., Cauley, J. A., Johnson, K. C., Ma, X., … Wactawski-Wende, J. (2017). Oral Bisphosphonate Use and Lung Cancer Incidence among Postmenopausal Women. JOURNAL OF THORACIC ONCOLOGY, 12(11), S1564–S1565.

Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI)
Horn, L., Leal, T. A., Oxnard, G., Wakelee, H., Blumenschein, G. R., Waqar, S., … Reckamp, K. (2017). Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI). JOURNAL OF THORACIC ONCOLOGY, 12(11), S1556.

The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC)
Love, N., Birrer, M. J., Hecht, J. R., Wakelee, H. A., Chen, G. Q., Deutsch, M. A., … Ziel, K. (2017). The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC). JOURNAL OF CLINICAL ONCOLOGY, 35(8).

EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor
Goldman, J. W., Karlovich, C., Sequist, L., Melnikova, V., Franovic, A., Gadgeel, S. M., … Wakelee, H. A. (2018). EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO PRECISION ONCOLOGY, 2, 1–13.

Response to Ensartinib in TKI Naive ALK plus NSCLC Patients
Wakelee, H., Sanborn, R., Nieva, J., Waqar, S., Brzezniak, C., Bauman, J., … Horn, L. (2017). Response to Ensartinib in TKI Naive ALK plus NSCLC Patients. JOURNAL OF THORACIC ONCOLOGY, 12(11), S1826.

The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC) and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC)
Ziel, K., Birrer, M. J., Hecht, J. R., Wakelee, H. A., Chen, G. Q., Deutsch, M. A., … Love, N. (2017). The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC) and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC). JOURNAL OF CLINICAL ONCOLOGY, 35.

Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., & Wakelee, H. A. (2019). Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. CLINICAL LUNG CANCER, 20(2), E208–E217.

A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
Das, M., Padda, S. K., Frymoyer, A., Molina, J., Adjei, A., Lensing, J. L., … Wakelee, H. A. (2018). A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 82(3), 541–50.

Caution Needed for Analyzing the Risks of Second Cancers
Han, S. S., Plevritis, S. K., & Wakelee, H. A. (2018). Caution Needed for Analyzing the Risks of Second Cancers. JOURNAL OF THORACIC ONCOLOGY, 13(9), E172–E173.

Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib
Wang, S. X. Y., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M. G., Diehn, M., … Neal, J. W. (2019). Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. ANTI-CANCER DRUGS, 30(5), 537–41.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2019). First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. JOURNAL OF CLINICAL ONCOLOGY, 37(12), 946-+.

Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.
Hann, C. L., Scherpereel, A., Hellyer, J. A., & Wakelee, H. A. (2019). Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (39), 543–52.

Increased Galectin-1 Expression in Thymic Epithelial Tumors
Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., & Le, Q.-T. (2019). Increased Galectin-1 Expression in Thymic Epithelial Tumors. CLINICAL LUNG CANCER, 20(3), E356–E361.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., … Gautschi, O. (2019). Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of Oncology : Official Journal of the European Society for Medical Oncology.

Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., … Gensheimer, M. F. (2018). Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. CLINICAL LUNG CANCER, 19(5), E581–E588.

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019). Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Lung Cancer (Amsterdam, Netherlands), 133, 144–50.

Lung cancer incidence in never smokers
Wakelee, H. A., Chang, E. T., Gomez, S. L., Keegan, T. H., Feskanich, D., Clarke, C. A., … West, D. W. (2007). Lung cancer incidence in never smokers. JOURNAL OF CLINICAL ONCOLOGY, 25(5), 472–78.

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer
Horn, L., Bauml, J., Forde, P. M., Davis, K. L., Myall, N. J., Sasane, M., … Johnson, B. E. (2019). Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. LUNG CANCER, 128, 74–90.

Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam
Nguyen, K.-S. H., Stehr, H., Zhou, L., Anh-Hoa Nguyen, Pham Nhu Hiep, Nguyen Van Cau, … Neal, J. W. (2018). Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. JOURNAL OF GLOBAL ONCOLOGY, 4.

Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer
Sun, T. Y., Niu, X., Chakraborty, A., Neal, J. W., & Wakelee, H. A. (2019). Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 14(2), E21–E24.

Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer
Tseng, D., Padda, S. K., & Wakelee, H. A. (2018). Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 13(6), 741–44.

Circulating tumor DNA testing in advanced non-small cell lung cancer
Moding, E. J., Diehn, M., & Wakelee, H. A. (2018). Circulating tumor DNA testing in advanced non-small cell lung cancer. LUNG CANCER, 119, 42–47.

Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy
Shukla, N. D., Salahudeen, A. A., Taylor, G. A., Ramalingam, S. S., Vokes, E. E., Goss, G. D., … Wakelee, H. A. (2018). Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. CLINICAL LUNG CANCER, 19(5), 377–86.

Review of the current targeted therapies for non-small-cell lung cancer
Nguyen, K.-S. H., Neal, J. W., & Wakelee, H. (2014). Review of the current targeted therapies for non-small-cell lung cancer. WORLD JOURNAL OF CLINICAL ONCOLOGY, 5(4), 576–87.

MET inhibitors in combination with other therapies in non-small cell lung cancer
Padda, S., Neal, J. W., & Wakelee, H. A. (2012). MET inhibitors in combination with other therapies in non-small cell lung cancer. TRANSLATIONAL LUNG CANCER RESEARCH, 1(4), 238–53.

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Hong, D., Rasco, D., Veeder, M., Luke, J. J., Chandler, J., Balmanoukian, A., … Borazanci, E. (2019). A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Oncology, 1–10.

Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2019). Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. ONCOLOGIST, 24(6), 836–43.

A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2016). A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Plasma genotyping of patients enrolled on the expansion phase VII trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC).
Horn, L., Wakelee, H. A., Reckamp, K. L., Blumenschein, G. R., Infante, J. R., Carter, C. A., … Lovly, C. M. (2016). Plasma genotyping of patients enrolled on the expansion phase VII trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.
Chabon, J. ., Simmons, A., Newman, A. M., Lovejoy, A. F., Esfahani, M. S., Haringsma, H., … Diehn, M. (2016). Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Updated results from TIGER-X, a phase open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).
Goldman, J. W., Soria, J.-C., Wakelee, H. A., Camidge, D. R., Gadgeel, S. M., Yu, H. A., … Sequis, L. V. (2016). Updated results from TIGER-X, a phase open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
Hellyer, J. A., Stehr, H., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., … Wakelee, H. A. (2019). Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 134, 42–45.

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non small-cell lung cancer.
Antonia, S. J., Kim, S.-W., Spira, A. I., Ahn, M.-J., Ou, S.-H. I., Stjepanovic, N., … Segal, N. H. (2016). Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.
Wakelee, H. A., Gadgeel, S. M., Goldman, J. W., Reckamp, K. L., Karlovich, C. A., Melnikova, V., … Sequist, L. V. (2016). Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC)
Horn, L., Whisenant, J. G., Wakelee, H., Reckamp, K. L., Qiao, H., Du, L., … Lovly, C. M. (2019). Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC). ANNALS OF ONCOLOGY, 30, 44.

Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., … Diehn, M. (2016). Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.
Horn, L., Whisenant, J. G., Wakelee, H., Reckamp, K. L., Qiao, H., Leal, T. A., … Lovly, C. M. (2019). Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019). Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes". Lung Cancer (Amsterdam, Netherlands).

TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.
Yang, J. C.-H., Popat, S., Novello, S., Groen, H. J. M., Perol, M., Felip, E., … Wakelee, H. A. (2016). TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC-Outcomes based on chemotherapy subsets.
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., … Schiller, J. H. (2016). E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC-Outcomes based on chemotherapy subsets. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.
Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M., … Diehn, M. (2019). Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.
Hellyer, J. A., Gubens, M. A., Cunanan, K. M., Padda, S. K., Burns, M., Spittler, A. J., … Loehrer, P. J. (2019). Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer (Amsterdam, Netherlands), 137, 71–75.

Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes
Moding, E. J., Nabet, B. Y., Liu, Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2019). Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 105(1), S113.

ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.
Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., … Diehn, M. (2019). ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.
Neal, J. W., Hausrath, D., Wakelee, H. A., Cunanan, K., Liu, S. V., Banwait, M., … Piotrowska, Z. (2019). Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC:An ETCTN California cancer consortium phase I study.
Riess, J. W., Groshen, S. G., Reckamp, K. L., Wakelee, H. A., Oxnard, G. R., Padda, S. K., … Gandara, D. R. (2019). Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC:An ETCTN California cancer consortium phase I study. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Phase I/II study to evaluate the safety and preliminary activity of nivolumab in combination with vorolanib in patients with refractory thoracic tumors
Whisenant, J. G., Beckerman, K., Borghaei, H., Owonikoko, T., Patel, J., Shyr, Y., … Horn, L. (2019). Phase I/II study to evaluate the safety and preliminary activity of nivolumab in combination with vorolanib in patients with refractory thoracic tumors. CANCER RESEARCH, 79(13).

Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients
Liu, X., Ao, Z., Preiss, J. S., Neal, J., Zhou, L. Y., Sambucetti, L., & Wakelee, H. A. (2019). Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Adjuvant PD-(L)1 Checkpoint Inhibitors
Hellyer, J., & Wakelee, H. (2019). Adjuvant PD-(L)1 Checkpoint Inhibitors. JOURNAL OF THORACIC ONCOLOGY, 14(10), S156–S157.

Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
Wakelee, H., Reckamp, K., Leal, T., Chiappori, A., Waqar, S., Zeman, K., … Horn, L. (2019). Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib. JOURNAL OF THORACIC ONCOLOGY, 14(10), S566.

STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
Skoulidis, F., Arbour, K., Hellmann, M., Patil, P., Marmarelis, M., Owen, D., … Heymach, J. (2019). STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. JOURNAL OF THORACIC ONCOLOGY, 14(10), S294–S295.

Phase I/II Study of Nivolumab and Vorolanib in Patients with Refractory Thoracic Tumors
Whisenant, J., Beckermann, K., Borghaei, H., Owonikoko, T., Patel, J., Berry, L., … Horn, L. (2019). Phase I/II Study of Nivolumab and Vorolanib in Patients with Refractory Thoracic Tumors. JOURNAL OF THORACIC ONCOLOGY, 14(10), S445–S446.

A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens
Karacosta, L., Anchang, B., Ignatiadis, N., Kimmey, S., Benson, J., Shrager, J., … Plevritis, S. (2019). A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens. JOURNAL OF THORACIC ONCOLOGY, 14(10), S226–S227.

Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors
Hellyer, J., Padda, S., Vali, S., Das, A., Sikora, H., Husain, Z., … Wakelee, H. (2019). Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors. JOURNAL OF THORACIC ONCOLOGY, 14(10), S580.

Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LW: Results from the phase II, ASCEND-7 study
Barlesi, F., Kim, D.-W., Bertino, E. M., van den Bent, M. J., Wakelee, H., Wen, P. Y., … Chow, L. Q. (2019). Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LW: Results from the phase II, ASCEND-7 study. ANNALS OF ONCOLOGY, 30, 143-+.

E1505: Adjuvant Chemotherapy plus /- Bevacizumab for Early Stage NSCLC: Updated Chemotherapy Subset Analysis
Wakelee, H., Dahlberg, S., Keller, S., Tester, W., Aisner, S., Rothman, J., … Schiller, J. (2019). E1505: Adjuvant Chemotherapy plus /- Bevacizumab for Early Stage NSCLC: Updated Chemotherapy Subset Analysis. JOURNAL OF THORACIC ONCOLOGY, 14(10), S271.

Outcome Disparities in American Indian/Alaskan Natives with Advanced Stage Lung Cancer
Hellyer, J., Cunanan, K., Wakelee, H., & Han, S. (2019). Outcome Disparities in American Indian/Alaskan Natives with Advanced Stage Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 14(10), S668.

Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) metastatic to the brain
Chow, L. Q., Barlesi, F., Bertino, E. M., van den Bent, M. J., Wakelee, H., Wen, P. Y., … Kim, D.-W. (2019). Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) metastatic to the brain. ANNALS OF ONCOLOGY, 30, 602–3.

Making the Most of WCLC: A Guide for First Time Attendees
Wakelee, H., & Bunn, B. (2019). Making the Most of WCLC: A Guide for First Time Attendees. JOURNAL OF THORACIC ONCOLOGY, 14(10), S1115–S1116.

Evaluating Racial Differences in KRAS-Mutant Non-Small Cell Lung Cancer
Aredo, J., Padda, S., Kunder, C., Han, S., & Wakelee, H. (2019). Evaluating Racial Differences in KRAS-Mutant Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Checkpoint Inhibitor Combinations Among Themselves and with Chemotherapy
Mathias, C., & Wakelee, H. (2019). Checkpoint Inhibitor Combinations Among Themselves and with Chemotherapy. JOURNAL OF THORACIC ONCOLOGY, 14(11), S1166.

Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)
Leal, T., Wakelee, H., Reckamp, K. L., Chiappori, A., Oxnard, G. R., Waqar, S. N., … Horn, L. (2019). Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2). JOURNAL OF THORACIC ONCOLOGY, 14(11), S1171–S1172.

Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice
Drakaki, A., Luhn, P., Wakelee, H., Dhillon, P. K., Kent, M., Shim, J., … Gutzmer, R. (2019). Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice. ANNALS OF ONCOLOGY, 30, 16–17.

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC.
Hellmann, M. D., Nabet, B. Y., Rizvi, H., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P., … Diehn, M. (2020). Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort.
Wang, A., Kubo, J., Luo, J., Desai, M., Hedlin, H., Henderson, M., … Wakelee, H. A. (2015). Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 26(1), 221–30.

Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).
Horn, L., Whisenant, J. G., Wakelee, H., Reckamp, K. L., Qiao, H., Du, L., … Lovly, C. M. (2019). Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC). Annals of Oncology : Official Journal of the European Society for Medical Oncology, 30 Suppl 2, ii48.

Prediction of PD-1 immunotherapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model.
Wakelee, H., Aredo, J., Vali, S., Singh, N. K., Vasista, S. V., Mitra, U., … Padda, S. K. (2018). Prediction of PD-1 immunotherapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29 Suppl 8, viii510–viii511.

Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).
Wakelee, H., Reckamp, K. L., Leal, T. A., Patel, S. P., Blumenschein, G., Shum, E., … Horn, L. (2018). Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29 Suppl 8, viii541–viii542.

eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients.
Horn, L., Wu, Y.-L., Reck, M., Wakelee, H., Liang, C., Harrow, K., … Mok, T. (2018). eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29 Suppl 8, viii543.

Integrating genomic features for non-invasive early lung cancer detection
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., … Diehn, M. (2020). Integrating genomic features for non-invasive early lung cancer detection. NATURE.

Feasibility and design of a cloud-based digital platform in patients with advanced cancer.
Roy, M., Hall, E. T., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., … Ramchandran, K. (2019). Feasibility and design of a cloud-based digital platform in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(27).

Impact of dual-eligible status on survival in Medicare patients with lung cancer.
Ragavan, M. V., Gardner, R., Cunanan, K., Sundaram, V., Wakelee, H. A., & Han, S. S. (2019). Impact of dual-eligible status on survival in Medicare patients with lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(27).

Integrating genomic features for non-invasive early lung cancer detection.
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., … Diehn, M. (2020). Integrating genomic features for non-invasive early lung cancer detection. Nature, 580(7802), 245–251.

Prognostic impact of KRAS mutation subtype and concurrent genetic mutations in non-small cell lung cancer.
Aredo, J., Padda, S. K., Kunder, C., Han, S. S., & Wakelee, H. A. (2018). Prognostic impact of KRAS mutation subtype and concurrent genetic mutations in non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Adjuvant Chemotherapy.
Hellyer, J. A., & Wakelee, H. A. (2020). Adjuvant Chemotherapy. Thoracic Surgery Clinics, 30(2), 179–85.

Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2020). Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. NATURE CANCER, 1.

A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.
Riess, J. W., Jahchan, N. S., Das, M., Zach Koontz, M., Kunz, P. L., Wakelee, H. A., … Neal, J. W. (2020). A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treatment and Research Communications, 23, 100174.

Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).
Marcoux, N., Gettinger, S. N., O'Kane, G. M., Arbour, K. C., Neal, J. W., Husain, H., … Sequist, L. V. (2018). Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC). JOURNAL OF CLINICAL ONCOLOGY, 36(15).

Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments.
Salahudeen, A. A., Zhu, J., Ju, J., Giangarra, V., Montesclaros, L., Sapida, J., … Kuo, C. J. (2018). Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments. JOURNAL OF CLINICAL ONCOLOGY, 36(15).

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.
Whisenant, J. G., Trama, A., Torri, V., De Toma, A., Viscardi, G., Cortellini, A., … Horn, L. (2020). TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. Cancer Cell.

The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer.
Smeltzer, M. P., Wynes, M. W., Lantuejoul, S., Soo, R., Ramalingam, S. S., Varella-Garcia, M., … Hirsch, F. R. (2020). The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Garassino, M. C., Whisenant, J. G., Huang, L.-C. C., Trama, A., Torri, V., Agustoni, F., … Horn, L. (2020). COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. The Lancet. Oncology.

US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors.
Papadopoulos, K. P., Borazanci, E., Shaw, A. T., Katayama, R., Shimizu, Y., Zhu, V. W., … Ou, S.-H. I. (2020). US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.
Zhou, M., Joshi, N., Raj, K. P., Wakelee, H., & Neal, J. W. (2020). PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. Clinical Lung Cancer.

eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients
Horn, L., Wu, Y.-L., Reck, M., Wakelee, H. A., Liang, C., Tan, F., … Mok, T. (2018). eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients. JOURNAL OF CLINICAL ONCOLOGY, 36(15).

QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.
Padda, S. K., Brzezniak, C. E., Waqar, S. N., Wakelee, H. A., Ma, P. C., Rose, M. G., … Morgensztern, D. (2018). QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 36(15).

Real-world treatment patterns and survival of BRAF V600-mutated metastatic non-small cell lung cancer patients.
Horn, L., Bauml, J., Forde, P. M., Davis, K. L., Myall, N. J., Sasane, M., … Johnson, B. E. (2018). Real-world treatment patterns and survival of BRAF V600-mutated metastatic non-small cell lung cancer patients. JOURNAL OF CLINICAL ONCOLOGY, 36(15).

A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.
Hong, D. S., Rasco, D. W., Veeder, M. H., Luke, J. J., Chandler, J., Balmanoukian, A. S., … Borazanci, E. (2018). A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3
Selvaggi, G., Wakelee, H. A., Mok, T., Wu, Y.-L., Reck, M., Chiappori, A., … Liang, C. (2020). Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3. JOURNAL OF THORACIC ONCOLOGY, 15(10), E41–E42.

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H., … Diehn, M. (2020). Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell.

Everolimus in the treatment of metastatic thymic epithelial tumors.
Hellyer, J. A., Ouseph, M. M., Padda, S. K., & Wakelee, H. A. (2020). Everolimus in the treatment of metastatic thymic epithelial tumors. Lung Cancer (Amsterdam, Netherlands), 149, 97–102.

KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., … Diehn, M. (2020). KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Discovery of a novel shared tumor antigen in human lung cancer.
Tseng, D., Chiou, S.-H., Yang, X., Reuben, A., Wilhelmy, J., McSween, A., … Davis, M. (2020). Discovery of a novel shared tumor antigen in human lung cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.
Moding, E. J., Esfahani, M. S., Nabet, B., Liu, Y., Chabon, J. J., He, J., … Diehn, M. (2020). A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
Ji, J., Aredo, J., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., … Riess, J. W. (2020). Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience.
Piper-Vallillo, A., Rotow, J. K., Aredo, J., Shaverdashvili, K., Luo, J., Carlisle, J. W., … Piotrowska, Z. (2020). High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies.
Cortellini, A., Dingemans, A.-M. C., Arrieta, O., Baena, J., Brighenti, M., Felip, E., … Popat, S. (2020). Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies. CLINICAL CANCER RESEARCH, 26(18).

KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.
Binkley, M. S., Jeon, Y.-J. J., Nesselbush, M., Moding, E. J., Nabet, B. Y., Almanza, D., … Diehn, M. (2020). KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. Cancer Discovery.

Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)
Baena Espinar, J., Torri, V., Whisenant, J., Hirsch, F. R., Rogado, J., de Castro Carpeno, J., … Hellmann, M. (2020). Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion). ANNALS OF ONCOLOGY, 31, S1204–S1205.

Perioperative pembrolizumab plus platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study
Tsuboi, M., Luft, A., Ursol, G., Kato, T., Levchenko, E., Eigendorff, E., … Wakelee, H. A. (2020). Perioperative pembrolizumab plus platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study. ANNALS OF ONCOLOGY, 31, S801–S802.

Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma
Drakaki, A., Dhillon, P. K., Wakelee, H., Chui, S. Y., Shim, J., Kent, M., … Gutzmer, R. (2020). Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. ONCOIMMUNOLOGY, 9(1).

Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience.
Trama, A., Proto, C., Whisenant, J. G., Torri, V., Cortellini, A., Michielin, O., … Baena, J. (2020). Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. Cancer Cell.

Lung cancer incidence and risk factors in never-smoking Asian American, Native Hawaiian, and Pacific Islander women: The development of a multilevel integrated dataset of EHR, cancer registry, and environmental data
DeRouen, M. C., Shariff-Marco, S., Lichtensztajn, D., Jin, A., Daida, Y. G., Canchola, A. J., … Gomez, S. L. (2020). Lung cancer incidence and risk factors in never-smoking Asian American, Native Hawaiian, and Pacific Islander women: The development of a multilevel integrated dataset of EHR, cancer registry, and environmental data. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 29(6).

Two Cases of Pulmonary Tumor Thrombotic Microangiopathy Associated with ROS1-Rearranged Non-Small-Cell Lung Cancer.
Shah, A. T., Bernardo, R. J., Berry, G. J., Kudelko, K., & Wakelee, H. A. (2020). Two Cases of Pulmonary Tumor Thrombotic Microangiopathy Associated with ROS1-Rearranged Non-Small-Cell Lung Cancer. Clinical Lung Cancer.

Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer
Shukla, N. D., Salahudeen, A. A., Padda, S. K., Neal, J. W., Wakelee, H. A., & Kuo, C. J. (2018). Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer.
Park, M., Ho, D. Y., Wakelee, H. A., & Neal, J. W. (2020). Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer. Clinical Lung Cancer.

Lung cancer incidence and risk factors in never-smoking Asian American, Native Hawaiian, and Pacific Islander women: A multilevel dataset of electronic health record, cancer registry, and environmental data
DeRouen, M. C., Thompson, C., Canchola, A. J., Jin, A., Nie, S., Jain, J., … Gomez, S. L. (2020). Lung cancer incidence and risk factors in never-smoking Asian American, Native Hawaiian, and Pacific Islander women: A multilevel dataset of electronic health record, cancer registry, and environmental data. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 29(6).

Clinical implications of KEAP1-NFE2L2 mutations in non-small cell lung cancer.
Hellyer, J. A., Padda, S. K., Diehn, M., & Wakelee, H. A. (2020). Clinical implications of KEAP1-NFE2L2 mutations in non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice
Drakaki, A., Dhillon, P. K., Wakelee, H., Chui, S. Y., Shim, J., Kent, M., … Gutzmer, R. (2020). Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice. CANCER RESEARCH, 80(16).

Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice
Drakaki, A., Dhillon, P. K., Wakelee, H., Chui, S. Y., Shim, J., Kent, M., … Gutzmer, R. (2020). Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice. CANCER RESEARCH, 80(16).

Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.
Nesvet, J. C., Antilla, K. A., Pancirer, D. S., Lozano, A. X., Preiss, J. S., Ma, W., … Wang, S. X. (2021). Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. Clinical Chemistry.

Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang, M., Rodrigues, A. J., Pollom, E. L., Gibbs, I. C., Soltys, S. G., Hancock, S. L., … Li, G. (2021). Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. Journal of Neuro-Oncology.

Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report.
Aredo, J. V., Diehn, M., Berry, G. J., & Wakelee, H. A. (2020). Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report. Clinical Lung Cancer.

Smoking Behavior in Patients with Early Stage NSCLC: A Report from ECOG-ACRIN 1505 Trial.
Steuer, C. E., Jegede, O. A., Dahlberg, S. E., Wakelee, H. A., Keller, S. M., Tester, W. J., … Schiller, J. H. (2021). Smoking Behavior in Patients with Early Stage NSCLC: A Report from ECOG-ACRIN 1505 Trial. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.
Hellyer, J. A., Aredo, J. V., Das, M., Ramchandran, K., Padda, S. K., Neal, J. W., & Wakelee, H. A. (2021). Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival
van Meerbeeck, J., Dingemans, A. M., Horn, L., Torri, V., Whisenant, J., Wakelee, H., … Chorostowska, J. (2020). Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. EUROPEAN RESPIRATORY JOURNAL, 56.

Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
Aredo, J. V., Hellyer, J. A., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., … Wakelee, H. A. (2021). Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy. JOURNAL OF THORACIC ONCOLOGY, 16(1), S15.

Smoking Cessation After Lung Cancer Diagnosis and Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study
Choi, E., Luo, S., Tammemagi, M., Aredo, J., Marchand, L., Cheng, I., … Han, S. (2021). Smoking Cessation After Lung Cancer Diagnosis and Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study. JOURNAL OF THORACIC ONCOLOGY, 16(1), S40–S41.

Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series.
Myall, N. J., Lei, A. Q., & Wakelee, H. A. (2021). Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series. Translational Lung Cancer Research, 10(1), 487–95.

Evaluating the Role of Targeted Therapy in Lung Cancer
Wakelee, H. (2019). Evaluating the Role of Targeted Therapy in Lung Cancer. ONCOLOGY-NEW YORK, 33(12), 482–86.

Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.
Aredo, J. V., Mambetsariev, I., Hellyer, J. A., Amini, A., Neal, J. W., Padda, S. K., … Wakelee, H. A. (2021). Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

A review of immunotherapy for stage 3 and metastatic NSCLC & the rationale for the ECOG-ACRIN EA5181 study.
Varlotto, J. M., Sun, Z., Ky, B., Upshaw, J., Katz, S. I., Fitzgerald, T. J., … Pennell, N. A. (2021). A review of immunotherapy for stage 3 and metastatic NSCLC & the rationale for the ECOG-ACRIN EA5181 study. The Oncologist.

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
White, M. N., Piotrowska, Z., Stirling, K., Liu, S. V., Banwait, M. K., Cunanan, K., … Neal, J. W. (2021). Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clinical Lung Cancer.

Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders.
Beckermann, K., Bestvina, C. M., Whisenant, J. G., Borghaei, H., Owonikoko, T. K., Berry, L. D., … Horn, L. (2020). Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders. JOURNAL OF CLINICAL ONCOLOGY, 38(15).

Phase II randomized trial of carboplatin plus pemetrexed plus bevacizumab, plus /- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked.
Bodor, J. N., Patel, J. D., Ross, E. A., Litwin, S., Clapper, M., Levy, B. P., … Treat, J. (2020). Phase II randomized trial of carboplatin plus pemetrexed plus bevacizumab, plus /- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked. JOURNAL OF CLINICAL ONCOLOGY, 38(15).

A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer
Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., … Diehn, M. (2020). A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Is smoking a risk factor for second primary lung cancer
Aredo, J., Luo, S. J., Gardner, R., Hickey, T. P., Riley, T. L., Wilkens, L. R., … Han, S. S. (2020). Is smoking a risk factor for second primary lung cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival
Whisenant, J. G., Torri, V., Huang, L.-C., Trama, A., Paz-Ares, L. G., Felip, E., … Garassino, M. C. (2020). Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. JOURNAL OF CLINICAL ONCOLOGY, 38(18).

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery.
Chiou, S.-H. H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., … Davis, M. M. (2021). Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 54(3), 586–602.e8.

Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo.
Foggetti, G., Li, C., Cai, H., Hellyer, J. A., Lin, W.-Y., Ayeni, D., … Politi, K. (2021). Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo. Cancer Discovery.

Tobacco Smoking and Risk of Second Primary Lung Cancer.
Aredo, J. V., Luo, S. J., Gardner, R. M., Sanyal, N., Choi, E., Hickey, T. P., … Han, S. S. (2021). Tobacco Smoking and Risk of Second Primary Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Metabolomic profiling for second primary lung cancer: A pilot case-control study.
Aredo, J. V., Purington, N., Su, L., Luo, S. J., Diao, N., Christiani, D. C., … Han, S. S. (2021). Metabolomic profiling for second primary lung cancer: A pilot case-control study. Lung Cancer (Amsterdam, Netherlands), 155, 61–67.

Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., … Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137–39.

Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib
White, M., Neal, J. W., Gardner, R. M., Cunanan, K. M., Das, M., Padda, S. K., … Wakelee, H. (2021). Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib. JOURNAL OF THORACIC ONCOLOGY, 16(4), S773–S774.

Women in cancer research and oncology
Joyce, J., Wakelee, H., Davis, M. B., Teo, S.-H., Bell, S., & Rendo, V. (2021). Women in cancer research and oncology. CANCER CELL, 39(3), 285–87.

Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers
Roy, M., Fardeen, T., Generalova, O., Hall, E., Cunanan, K., Das, M., … Ramchandran, K. (2021). Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma
Aredo, J., Wakelee, H. A., Neal, J., & Padda, S. (2021). Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors
Padda, S., Whisenant, J., Neal, J., York, S., Iams, W., Neuss, M., … Horn, L. (2021). Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST
Su, C. C., Wu, J., Neal, J., Popat, R., Backhus, L., Leung, A., … Han, S. (2021). Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Impact of Medicaid Enrollment on Mortality in Elderly Dual-Eligible Lung Cancer Patients
Ragavan, M., Gardner, R., Cunanan, K., Wakelee, H., & Han, S. (2021). Impact of Medicaid Enrollment on Mortality in Elderly Dual-Eligible Lung Cancer Patients. JOURNAL OF THORACIC ONCOLOGY, 16(3), S306.

COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT)
Whisenant, J., Wong, S., Torri, V., Revuelta, J., Halmos, B., Ceresoli, G., … Tapan, U. (2021). COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT). JOURNAL OF THORACIC ONCOLOGY, 16(3), S297.

The Mutational Landscape in South Asian Patients with Non-Small Cell Lung Cancer at an US Academic Medical Center
Roy, M., & Wakelee, H. A. (2021). The Mutational Landscape in South Asian Patients with Non-Small Cell Lung Cancer at an US Academic Medical Center. JOURNAL OF THORACIC ONCOLOGY, 16(3), S428.

RAS Precision Medicine Trans-Atlantic Partnership: Multi-Centre Pooled Analysis of RAS Pathway Mutations in Advanced NSCLC
Adderley, H., Aldea, M., Aredo, J., Carter, M., Church, M., Blackhall, F., … Lindsay, C. (2021). RAS Precision Medicine Trans-Atlantic Partnership: Multi-Centre Pooled Analysis of RAS Pathway Mutations in Advanced NSCLC. JOURNAL OF THORACIC ONCOLOGY, 16(3), S696.

Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.
Selvaggi, G., Wu, Y., Wang, Z., Wu, G., Poddubskaya, E., Reck, M., … Wakelee, H. A. (2021). Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3. JOURNAL OF THORACIC ONCOLOGY, 16(3), S232–S233.

Time to First Progression in Patients with NSCLC with Brain Metastases Receiving 3rd Generation TKI alone vs TKI plus Brain Radiation
Thomas, N., Myall, N., Sun, F., Patil, T., Mushtaq, R., Yu, C., … Mccoach, C. (2021). Time to First Progression in Patients with NSCLC with Brain Metastases Receiving 3rd Generation TKI alone vs TKI plus Brain Radiation. JOURNAL OF THORACIC ONCOLOGY, 16(3), S591–S592.

Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer
Padda, S. K., Aredo, J., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., … Wakelee, H. A. (2021). Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. JCO PRECISION ONCOLOGY, 5, 153–62.

Coping Strategy Influences Quality of Life in Patients With Advanced Lung Cancer by
Shah, A. T., Bernardo, R. J., Berry, G. J., Kudelko, K., & Wakelee, H. A. (2021). Coping Strategy Influences Quality of Life in Patients With Advanced Lung Cancer by. CLINICAL LUNG CANCER, 22(2), E153–E156.

Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., … Diehn, M. (2021). Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.
Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., … Diehn, M. (2021). Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Integrating electronic health record, cancer registry, and geospatial data to study lung cancer in Asian American, Native Hawaiian and Pacific Islander ethnic groups.
DeRouen, M. C., Thompson, C. A., Canchola, A. J., Jin, A., Nie, S., Wong, C., … Gomez, S. L. (2021). Integrating electronic health record, cancer registry, and geospatial data to study lung cancer in Asian American, Native Hawaiian and Pacific Islander ethnic groups. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology.

Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
Su, C. C., Wu, J. T., Neal, J. W., Popat, R. A., Kurian, A. W., Backhus, L. M., … Han, S. S. (2021). Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type.
Padda, S. K., Gokmen-Polar, Y., Hellyer, J. A., Badve, S. S., Singh, N. K., Vasista, S. M., … Wakelee, H. A. (2021). Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type. Oncotarget, 12(12), 1178–1186.

Treatment of Thymic Neoplasms by Drug Therapy
Padda, S. K., & Wakelee, H. A. (2018). Treatment of Thymic Neoplasms by Drug Therapy. MODERN THORACIC ONCOLOGY, VOL 3: ESOPHAGUS, MEDIASTINUM, CHEST WALL, AND DIAPHRAGM, 229–241.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).
Rolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., … Gandara, D. (2021). Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC). Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer.
Choi, E., Sanyal, N., Ding, V. Y., Gardner, R. M., Aredo, J. V., Lee, J., … Han, S. S. (2021). Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer. Journal of the National Cancer Institute.

A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.
Aredo, J. V., Wakelee, H. A., & Han, S. S. (2021). A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 16(8), e59–e60.

Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females.
DeRouen, M. C., Canchola, A. J., Thompson, C. A., Jin, A., Nie, S., Wong, C., … Gomez, S. L. (2021). Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females. Journal of the National Cancer Institute.

EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., & Neal, J. W. (2021). EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer.

Radiological tumour classification across imaging modality and histology
Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., … Li, R. (2021). Radiological tumour classification across imaging modality and histology. NATURE MACHINE INTELLIGENCE.

Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
Waliany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., … Neal, J. W. (2021). Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.
Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., … McCoach, C. E. (2021). Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn, L., Wang, Z., Wu, G., Poddubskaya, E., Mok, T., Reck, M., … Wu, Y.-L. (2021). Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncology.

Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2020). Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nature Cancer, 1(2), 176–183.

Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., … Ramchandran, K. (2021). Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer. Journal of Patient-Reported Outcomes, 5(1), 91.

Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management
Filsoof, D., Padda, S. K., Garcia, P., Stedman, M., Neal, J. W., Wakelee, H. A., … Katsumoto, T. R. (2021). Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC.

Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study
Filsoof, D., Im, J., Garcia, P., Stedman, M., Anand, S., Neal, J. W., … Raj, R. (2021). Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC.

The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer
Choi, E., Luo, S., Aredo, J., Wilkens, L., Leung, A., Le Marchand, L., … Han, S. (2021). The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC.

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip, E., Altorki, N., Zhou, C., Csoszi, T., Vynnychenko, I., Goloborodko, O., … Wakelee, H. (2021). Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet (London, England).

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.
Yang, J. C.-H., Reckamp, K. L., Kim, Y.-C., Novello, S., Smit, E. F., Lee, J.-S., … Wakelee, H. (2021). Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports, 2(2), 100114.

Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study.
Luo, S. J., Choi, E., Aredo, J. V., Wilkens, L. R., Tammemagi, M. C., Le Marchand, L., … Han, S. S. (2021). Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study. JNCI Cancer Spectrum, 5(5), pkab076.

Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
Lau, B., No, H., (Fred) Wu, Y., Devine, M., Ko, R., Loo, B., … Vitzthum, L. (2021). Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. LIPPINCOTT WILLIAMS & WILKINS.

IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
Felip, E., Vallieres, E., Zhou, C., Wakelee, H., Bondarenko, I., Sakai, H., … Altorki, N. K. (2021). IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. ANNALS OF ONCOLOGY. ELSEVIER.

SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab plus tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT)
Dziadziuszko, R., Ahn, M.-J., Kelly, K. A., Popat, S., Wakelee, H., Baird, A.-M., … Bradley, J. D. (2021). SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab plus tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT). ANNALS OF ONCOLOGY. ELSEVIER.

RAS precision medicine trans-Atlantic partnership: Multi-centre analysis of RAS and NF1 co-mutations in advanced NSCLC
Adderley, H., Aldea, M., Aredo, J., Carter, M., Church, M., Ghaus, A., … Lindsay, C. (2021). RAS precision medicine trans-Atlantic partnership: Multi-centre analysis of RAS and NF1 co-mutations in advanced NSCLC. ANNALS OF ONCOLOGY. ELSEVIER.

Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., … Vitzthum, L. (2021). Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 111(3S), e435.

A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR).
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., … Diehn, M. (2021). A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR). International Journal of Radiation Oncology, Biology, Physics, 111(3S), S89–S90.

Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020
Chiang, R. S., Glover, M., Hui, G., Desai, A., Wakelee, H. A., Lythgoe, M., & Khaki, A. R. (2021). Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation.
Dziadziuszko, R., Ahn, M. J., Kelly, K., Popat, S., Wakelee, H. A., Baird, A. M., … Bradley, J. D. (2021). SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation. International Journal of Radiation Oncology, Biology, Physics, 111(3S), e420–e421.

A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., … Han, S. (2021). A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
Altorki, N., Felip, E., Zhou, C., Vallieres, E., Moiseyenko, V., Smolin, A., … Wakelee, H. (2021). IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials
Smeltzer, M., Bunn, P. A., Clark, R., Arndt, R., Pruett, C., Roy, U., … Scagliotti, G. (2021). International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening
Su, C., Choi, E., Wu, J., Neal, J., Kurian, A., Backhus, L., … Han, S. (2021). Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

The Association of Bevacizumab with a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505 in Completely Resected Stage IB-IIIA NSCLC
Varlotto, J., Wang, Y., Sun, Z., Wakelee, H., Ramalingam, S., & Schiller, J. (2021). The Association of Bevacizumab with a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505 in Completely Resected Stage IB-IIIA NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
Padda, S. K., Reckamp, K. L., Koczywas, M., Neal, J. W., Kawashima, J., Kong, S., … Wakelee, H. A. (2021). A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology.

Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts.
Wong, S. K., Whisenant, J. G., Bestvina, C. M., Berry, L. D., Owonikoko, T. K., Sanborn, R. E., … Beckermann, K. (2021). Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.
Aredo, J. V., Hellyer, J. A., Neal, J. W., & Wakelee, H. A. (2021). Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 16(12), 1994–1998.

Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
Lau, B., No, H. J., Wu, Y. F., Ko, R. B., Devine, M., Das, M., … Vitzthum, L. (2021). Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Wakelee, H. A., Altorki, N. K., Zhou, C., Csoszi, T., Vynnychenko, I. O., Goloborodko, O., … Felip, E. (2021). IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer
Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., … Vitzthum, L. (2021). Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR)
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., … Diehn, M. (2021). A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
Varlotto, J. M., Sun, Z., Ramalingam, S. S., Wakelee, H. A., Lovly, C. M., Oettel, K. R., … Pennell, N. (2021). Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation
Dziadziuszko, R., Ahn, M. J., Kelly, K., Popat, S., Wakelee, H. A., Baird, A. M., … Bradley, J. D. (2021). SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.
Hellyer, J. A., White, M. N., Gardner, R. M., Cunanan, K., Padda, S. K., Das, M., … Wakelee, H. A. (2021). Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer.

Radiological tumor classification across imaging modality and histology.
Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., … Li, R. (2021). Radiological tumor classification across imaging modality and histology. Nature Machine Intelligence, 3, 787–798.

Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies.
Myall, N. J., Yu, H., Soltys, S. G., Wakelee, H. A., & Pollom, E. (2021). Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies. Neuro-Oncology Advances, 3(Suppl 5), v52–v62.

Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
White, M. N., Piper-Vallillo, A. J., Gardner, R. M., Cunanan, K., Neal, J. W., Das, M., … Wakelee, H. A. (2021). Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer.

The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.
Choi, E., Luo, S. J., Aredo, J. V., Backhus, L. M., Wilkens, L. R., Su, C. C., … Han, S. S. (2021). The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer. Journal of the National Cancer Institute.

Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.
Aredo, J. V., Wakelee, H. A., Neal, J. W., & Padda, S. K. (1800). Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications, 30, 100497.

IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
Zhou, C., Das Thakur, M., Srivastava, M. K., Zou, W., Xu, H., Ballinger, M., … Novello, S. (2021). IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. ANNALS OF ONCOLOGY. ELSEVIER.

Impact of the COVID-19 Pandemic on Global Lung Cancer Clinical Trials: Why it matters to people with lung cancer.
Roy, U. B., Baird, A.-M., Ciupek, A., Fox, J., Manley, E. J., Norris, K., … Smeltzer, M. P. (1800). Impact of the COVID-19 Pandemic on Global Lung Cancer Clinical Trials: Why it matters to people with lung cancer. JTO Clinical and Research Reports, 100269.

Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer.
Padda, S. K., Aredo, J. V., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., … Wakelee, H. A. (2021). Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. JCO Precision Oncology, 5, 153–162.

Progression Versus Radiation Treatment Changes After Stereotactic Ablative Radiation Therapy of a Liver Metastasis
No, H. J., Negrete, L. M., Pollom, E. L., Wakelee, H. A., Chang, D. T., & Vitzthum, L. K. (2022). Progression Versus Radiation Treatment Changes After Stereotactic Ablative Radiation Therapy of a Liver Metastasis. PRACTICAL RADIATION ONCOLOGY, 12(1), 1–2.

In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"
Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., … McCoach, C. E. (1800). In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?". Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 17(2), e12–e14.

ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Chow, L. Q., Barlesi, F., Bertino, E. M., van den Bent, M. J., Wakelee, H. A., Wen, P. Y., … Kim, D.-W. (1800). ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry.
Whisenant, J. G., Baena, J., Cortellini, A., Huang, L.-C., Lo Russo, G., Porcu, L., … Torri, V. (2022). A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
Goldman, J. W., Karlovich, C., Sequist, L. V., Melnikova, V., Franovic, A., Gadgeel, S. M., … Wakelee, H. A. (2018). EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2, 1–13.

International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials.
Smeltzer, M. P., Scagliotti, G. V., Wakelee, H. A., Mitsudomi, T., Roy, U. B., Clark, R. C., … Bunn, P. A. (2022). International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Lung Cancer in Never Smokers
Rivera, G. A., & Wakelee, H. (2016). Lung Cancer in Never Smokers. LUNG CANCER AND PERSONALIZED MEDICINE: CURRENT KNOWLEDGE AND THERAPIES, 893, 43–57.

Adjuvant therapy for early-stage non-small cell lung cancer: The breaking of a new dawn.
Altorki, N., Villena-Vargas, J., & Wakelee, H. (2022). Adjuvant therapy for early-stage non-small cell lung cancer: The breaking of a new dawn. The Journal of Thoracic and Cardiovascular Surgery.

Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC.
Varlotto, J. M., Wang, Y., Sun, Z., Wakelee, H. A., Ramalingam, S., & Schiller, J. (2022). Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC. JTO Clinical and Research Reports, 3(3), 100274.

Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
Felip, E., Altorki, N. K., Zhou, C., Vallieres, E., Vynnychenko, I. O., Akopov, A., … Wakelee, H. (2022). Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study. ANNALS OF ONCOLOGY. ELSEVIER.

Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors.
Singhal, S., Hellyer, J., Ouseph, M. M., Wakelee, H. A., & Padda, S. K. (2022). Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors. JTO Clinical and Research Reports, 3(5), 100323.

COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related Delays during the Omicron Wave: A Brief Report from the TERAVOLT Analysis.
Bestvina, C. M., Whisenant, J. G., Torri, V., Cortellini, A., Wakelee, H., Peters, S., … Baena, J. (2022). COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related Delays during the Omicron Wave: A Brief Report from the TERAVOLT Analysis. JTO Clinical and Research Reports, 100335.

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
Piper-Vallillo, A. J., Rotow, J. K., Aredo, J. V., Shaverdashvili, K., Luo, J., Carlisle, J. W., … Piotrowska, Z. (2022). High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clinical and Research Reports, 3(6), 100328.

Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., … Vitzthum, L. K. (2022). Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. International Journal of Radiation Oncology, Biology, Physics.

Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study.
Aredo, J. V., Choi, E., Ding, V. Y., Tammemagi, M. C., Ten Haaf, K., Luo, S. J., … Han, S. S. (2022). Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study. JNCI Cancer Spectrum, 6(3).

Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Vivian Huang, Y., Ryan, J., … Wu, S. M. (2022). Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. Circulation, 101161CIRCULATIONAHA121056730.

Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
Waliany, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., … Neal, J. W. (2022). Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. Clinical Lung Cancer.

A brief report on the mutational landscape in non-small cell lung cancer of South Asian patients: Comparison at a US and an Indian Institution.
Roy, M., Bal, A., Gupta, N., Prasad, K. T., Wakelee, H. A., & Singh, N. (2022). A brief report on the mutational landscape in non-small cell lung cancer of South Asian patients: Comparison at a US and an Indian Institution. Lung India : Official Organ of Indian Chest Society, 39(4), 315–318.

Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
Devine, M., Merriott, D. J., No, H. J., Lau, B., Say, C., Yoo, C., … Vitzthum, L. K. (2022). Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. Practical Radiation Oncology.

Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment.
Giustini, N. P., Patel, S. P., Myall, N. J., Fernando do Prado Moura, J., Kulkarni, A., Chao, R. C., … Bazhenova, L. (2022). Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment. JCO Precision Oncology, 6, e2100551.

IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC
Kenmotsu, H., Zhou, C., Altorki, N., Felip, E., Vallieres, E., Sugawara, S., … Wakelee, H. (2022). IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC. ANNALS OF ONCOLOGY. ELSEVIER.

ITMIG 2021 Tumor Board: a case of a 37-year-old man with TNM stage IVA thymoma.
Zielinski, M., Roden, A. C., Truong, M. T., Van Raemdonck, D., Komaki, R., Wakelee, H., & Szolkowska, M. (2022). ITMIG 2021 Tumor Board: a case of a 37-year-old man with TNM stage IVA thymoma. Mediastinum (Hong Kong, China), 6, 26.

Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes.
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., … Han, S. S. (2022). Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes. JCO Precision Oncology, 6, e2200220.

Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020.
Chiang, R. S., Desai, A., Glover, M. J., Hui, G., Ramchandran, K. J., Wakelee, H., … Khaki, A. R. (2022). Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020. Cancer Investigation, 1–6.

Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.
Hui, C., Qu, V., Wang, J.-Y. Y., von Eyben, R., Chang, Y.-C. C., Chiang, P.-L. L., … Pollom, E. (2022). Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. Journal of Neuro-Oncology.

High Levels of CD47 Expression in Thymic Epithelial Tumors
Sun, T. Y., Nguyen, B., Chen, S., Natkunam, Y., Padda, S., Van De Rijn, M., … Riess, J. (2022). High Levels of CD47 Expression in Thymic Epithelial Tumors. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

CD47 expression patterns in thymic epithelial tumors.
Sun, T. Y., Nguyen, B., Chen, S., Natkunam, Y., Padda, S. K., De Rijn, M. V., … Riess, J. W. (2022). CD47 expression patterns in thymic epithelial tumors. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Ancestry-based differences in gene alterations in non-small cell lung cancer: Realworld data using genetic ancestry analysis.
Miura, K., Shukuya, T., Greenstein, R., Kaplan, B. G., Wakelee, H. A., Kurokawa, K., … Takahashi, K. (2022). Ancestry-based differences in gene alterations in non-small cell lung cancer: Realworld data using genetic ancestry analysis. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC
Karacosta, L. G., Pancirer, D., Preiss, J., Shrager, J. B., Sung, A. W., Neal, J. W., … Plevritis, S. K. (2022). Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
Wakelee, H., Altorki, N., Felip, E., Vallieres, E., Vynnychenko, I. O., Akopov, A., … Zhou, C. (2022). IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Genomic characterization of thymic epithelial tumor from real-world data.
Kurokawa, K., Shukuya, T., Greenstein, R., Kaplan, B. G., Wakelee, H. A., Miura, K., … Takahashi, K. (2022). Genomic characterization of thymic epithelial tumor from real-world data. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
Riess, J. W., Krailo, M. D., Padda, S. K., Groshen, S. G., Wakelee, H. A., Reckamp, K. L., … Gandara, D. R. (2022). Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., … Ramchandran, K. (2022). Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer. JCO Oncology Practice, OP2200128.

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.
Aredo, J. V., Wakelee, H. A., Hui, A. B.-Y., Padda, S. K., Joshi, N. D., Guo, H. H., … Neal, J. W. (2022). Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer. Cancer Treatment and Research Communications, 33, 100659.

Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study
Felip, E., Altorki, N., Zhou, C., Vallieres, E., Vynnychenko, I., Akopov, A., … Wakelee, H. (2022). Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study. ONCOLOGY RESEARCH AND TREATMENT. KARGER.

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.
Ji, J., Aredo, J. V., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., … Riess, J. W. (2023). Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study. JTO Clinical and Research Reports, 4(3), 100459.

Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Hui, C., Qu, V., Wang, J. Y., Von Eyben, R., Chang, Y. C., Chiang, P. L., … Pollom, E. (2022). Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.

Long term effect of radiotherapy on risk of second primary lung cancer and overall mortality among lung cancer patients
Choi, E., Lam, V. T., Aredo, J. A., Kumar, A. V., Wampfler, J., Wu, J. T., … Han, S. S. (2022). Long term effect of radiotherapy on risk of second primary lung cancer and overall mortality among lung cancer patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.
Sun, T. Y., Nguyen, B., Chen, S. B., Natkunam, Y., Padda, S., van de Rijn, M., … Riess, J. W. (2023). Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors. JTO Clinical and Research Reports, 4(4), 100498.

Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging.
Alhusaini, S., Lanman, T. A., Ko, R. B., Therkelsen, K. E., Eyben, R. V., Diehn, M., … Nagpal, S. (2023). Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging. Frontiers in Oncology, 13, 1139940.

Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.
Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., … Skoulidis, F. (2023). Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discovery.

Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents.
Lau, B., Wu, Y. F., No, H. J., Ko, R. B., Devine, M., Das, M. S., … Vitzthum, L. K. (2023). Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
Saad, M. B., Hong, L., Aminu, M., Vokes, N. I., Chen, P., Salehjahromi, M., … Wu, J. (2023). Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. The Lancet. Digital Health.

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H. H., Gao, S., … Spicer, J. D. (2023). Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. The New England Journal of Medicine.

Second Primary Lung Cancer among Lung Cancer Survivors Who Never Smoked
Choi, E., Su, C., Wu, J., Aredo, J., Neal, J., Leung, A., … Han, S. (2023). Second Primary Lung Cancer among Lung Cancer Survivors Who Never Smoked. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal.
Bestvina, C. M., Garassino, M. C., Neal, J. W., Wakelee, H. A., Diehn, M., & Vokes, E. E. (2023). Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2300258.

Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
Bodor, J. N., Patel, J. D., Wakelee, H. A., Levy, B. P., Borghaei, H., Pellini, B., … Treat, J. (2023). Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked. Clinical Lung Cancer.

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip, E., Altorki, N., Zhou, C., Vallieres, E., Martínez-Marti, A., Rittmeyer, A., … Wakelee, H. A. (2023). Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Annals of Oncology : Official Journal of the European Society for Medical Oncology.

Optimizing Lung Cancer Screening With Risk Prediction: Current Challenges and the Emerging Role of Biomarkers.
Wu, J. T.-Y., Wakelee, H. A., & Han, S. S. (2023). Optimizing Lung Cancer Screening With Risk Prediction: Current Challenges and the Emerging Role of Biomarkers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2301060.

The IASLC Early Lung Imaging Confederation (ELIC) Open-Source Deep Learning and Quantitative Measurement Initiative.
Lam, S., Wynes, M. W., Connolly, C., Ashizawa, K., Atkar-Khattra, S., Belani, C. P., … Avila, R. (2023). The IASLC Early Lung Imaging Confederation (ELIC) Open-Source Deep Learning and Quantitative Measurement Initiative. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
Wakelee, H. A., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., He, J., … Spicer, J. (2023). KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Software Application Profile: dynamicLM-a tool for performing dynamic risk prediction using a landmark supermodel for survival data under competing risks.
Fries, A. H., Choi, E., Wu, J. T., Lee, J. H., Ding, V. Y., Huang, R. J., … Han, S. S. (2023). Software Application Profile: dynamicLM-a tool for performing dynamic risk prediction using a landmark supermodel for survival data under competing risks. International Journal of Epidemiology.

Genomic characterization of thymic epithelial tumors in a real-world dataset.
Kurokawa, K., Shukuya, T., Greenstein, R. A., Kaplan, B. G., Wakelee, H., Ross, J. S., … Takahashi, K. (2023). Genomic characterization of thymic epithelial tumors in a real-world dataset. ESMO Open, 8(5), 101627.

Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
Gensheimer, M. F., Gee, H., Shirato, H., Taguchi, H., Snyder, J. M., Chin, A. L., … Diehn, M. (2023). Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. JAMA Oncology.

Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer.
Su, C. C., Wu, J. T., Choi, E., Myall, N. J., Neal, J. W., Kurian, A. W., … Han, S. S. (2023). Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer. JAMA Network Open, 6(9), e2335813.

EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)
Nassar, A., Adib, E., Feng, J., Aredo, J. V., Parikh, K., Harris, J. P., … Kim, S. Y. (2023). EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care
Reck, M., Srivastava, M. K., Wakelee, H. A., Felip, E., Altorki, N. K., Csoszi, T., … Zhou, C. (2023). IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC.
Hui, C., Wakelee, H. A., Neal, J. W., Ramchandran, K. J., Das, M., Nagpal, S., … Myall, N. (2023). CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC. International Journal of Radiation Oncology, Biology, Physics, 117(2S), e110.

Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
Choi, E., Luo, S. J., Ding, V. Y., Wu, J. T., Kumar, A. V., Wampfler, J., … Han, S. S. (2023). Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model. Cancer.

Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series
Franquiz, M., Waliany, S., Xu, A., Hnatiuk, A., Wu, S., Cheng, P., … Zhu, H. (2023). Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series. JACC: CardioOncology, 839–841.

A hybrid modelling approach for abstracting CT imaging indications by integrating natural language processing from radiology reports with structured data from electronic health records.
Khan, A., Wu, J., Choi, E., Graber-Naidich, A., Henry, S., Wakelee, H. A., … Han, S. S. (2023). A hybrid modelling approach for abstracting CT imaging indications by integrating natural language processing from radiology reports with structured data from electronic health records. CANCER PREVENTION RESEARCH. AMER ASSOC CANCER RESEARCH.

Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
Choi, E., Ding, V. Y., Luo, S. J., Ten Haaf, K., Wu, J. T., Aredo, J. V., … Han, S. S. (2023). Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US. JAMA Oncology.

Asian American Women's Experiences of Discrimination and Health Behaviors during the COVID-19 Pandemic.
Wang, K., Guan, A., Seto, J., Oh, D. L., Lau, K., Duffy, C., … Gomez, S. L. (2023). Asian American Women's Experiences of Discrimination and Health Behaviors during the COVID-19 Pandemic. Journal of Immigrant and Minority Health.

Risk factors for second primary lung cancer among breast cancer survivors
Choi, E., Lee, J., Wu, J. T., Wakelee, H. A., Schapira, L., Kurian, A. W., & Han, S. S. (2023). Risk factors for second primary lung cancer among breast cancer survivors. CANCER PREVENTION RESEARCH. AMER ASSOC CANCER RESEARCH.

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Zhou, C., Srivastava, M. K., Xu, H., Felip, E., Wakelee, H., Altorki, N., … Novello, S. (2023). Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial. Journal for Immunotherapy of Cancer, 11(10).

Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked.
Choi, E., Su, C. C., Wu, J. T., Aredo, J. V., Neal, J. W., Leung, A. N., … Han, S. S. (2023). Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked. JAMA Network Open, 6(11), e2343278.

Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
Burns, L., Hsu, C.-Y. Y., Whisenant, J. G., Marmarelis, M. E., Presley, C. J., Reckamp, K. L., … Tapan, U. (2023). Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT). Lung Cancer (Amsterdam, Netherlands), 186, 107423.

BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).
Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., … Le, X. (2023). BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Chemotherapy and immunotherapy in early-stage NSCLC: neoadjuvant vs adjuvant therapy.
Wakelee, H. (2023). Chemotherapy and immunotherapy in early-stage NSCLC: neoadjuvant vs adjuvant therapy. Clinical Advances in Hematology & Oncology : H&O, 21(12), 648–651.

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., … Vitzthum, L. K. (2023). Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer.

Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry.
Karacosta, L. G., Pancirer, D., Preiss, J. S., Benson, J. A., Trope, W., Shrager, J. B., … Plevritis, S. K. (2023). Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry. Scientific Reports, 13(1), 21781.

IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFß cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)
Altorki, N. K., Reck, M., Wakelee, H., Felip, E., Vallieres, E., Liersch, R., … Zhou, C. (2023). IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFß cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC). ANNALS OF ONCOLOGY. ELSEVIER.

RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer
Adderley, H., McDaid, W., Searle, J., Wilson, L., Marinello, A., Aldea, M., … Lindsay, C. R. (2023). RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer. ANNALS OF ONCOLOGY. ELSEVIER.

Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer NSCLC)
Spicer, J. D., Gao, S., Liberman, M., Kato, T., Tsuboi, M., Lee, S. H., … Wakelee, H. (2023). Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer NSCLC). ANNALS OF ONCOLOGY. ELSEVIER.

Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.
Hui, C., Marquez, C., Lau, B., Das, M., Myall, N. J., Roy, M., … Vitzthum, L. K. (2023). Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer. Clinical Lung Cancer.

IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC
Felip, E., Srivastava, M., Reck, M., Wakelee, H., Altorki, N., Vallieres, E., … Gitlitz, B. J. (2023). IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening
Aredo, J. V., Neal, J. W., Kunder, C. A., Ramchandran, K. J., Das, M. S., Myall, N. J., … Wakelee, H. A. (2023). Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.

Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
Nassar, A. H., Kim, S. Y., Aredo, J. V., Feng, J., Shepherd, F., Xu, C., … Goldberg, S. B. (2024). Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.
Beckermann, K. E., Bestvina, C. M., El Osta, B., Sanborn, R. E., Borghaei, H., Lammers, P. E., … Wakelee, H. (2024). A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors. JTO Clinical and Research Reports, 5(2), 100619.

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
Wakelee, H. A., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., He, J., … Spicer, J. (2023). KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 41(17_SUPPL), LBA100.

Top advances of the year: Perioperative therapy for lung cancer.
Aredo, J. V., & Wakelee, H. A. (2024). Top advances of the year: Perioperative therapy for lung cancer. Cancer.

Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC).
Spicer, J. D., Cascone, T., Wynes, M. W., Ahn, M.-J. J., Dacic, S., Felip, E., … Kelly, K. L. (2024). Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC). Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests.
Miura, K., Shukuya, T., Greenstein, R., Kaplan, B., Wakelee, H., Kurokawa, K., … Takahashi, K. (2024). Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests. Journal of the National Comprehensive Cancer Network : JNCCN, 1–10.

Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
Garassino, M. C., Wakelee, H. A., Spicer, J., Liberman, M., Kato, T., Tsuboi, M., … Gao, S. (2024). Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Association of napsin A-specific T cell clonotypes with durable clinical benefit to immunotherapy in patients with metastatic NSCLC
Miller, N. J., Baik, C. S., Neal, J. W., Houghton, A. M. G., Nair, V. S., Santana-Davila, R., … Tseng, D. (2024). Association of napsin A-specific T cell clonotypes with durable clinical benefit to immunotherapy in patients with metastatic NSCLC. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Racial and Ethnic Differences in Second Primary Lung Cancer Risk among Lung Cancer Survivors.
Choi, E., Hua, Y., Su, C. C., Wu, J. T., Neal, J. W., Leung, A. N., … Han, S. S. (2024). Racial and Ethnic Differences in Second Primary Lung Cancer Risk among Lung Cancer Survivors. JNCI Cancer Spectrum.

Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Florez, N., Patel, S. P., Wakelee, H., Bazhenova, L., Massarelli, E., Salgia, R., … Kim, E. (2024). Proceedings of the 1st biannual bridging the gaps in lung cancer conference. The Oncologist.

Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer.
Nassar, A. H., Jayakrishnan, R., Feng, J., Shepherd, F., Adib, E., Cheung, J. M., … Kim, S. Y. (2024). Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer, J. D., Garassino, M. C., Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., … Gao, S. (2024). Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England).

IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after =5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Wakelee, H. A., Altorki, N. K., Zhou, C., Csoszi, T., Vynnychenko, I. O., Goloborodko, O., … Felip, E. (2024). IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after =5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 42(17_SUPPL), LBA8035.

Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study.
Graber-Naidich, A., Choi, E., Wu, J. T., Ellis-Caleo, T. J., Neal, J., Wakelee, H. A., … Han, S. S. (2024). Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study. Clinical Lung Cancer.